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Ruohong Li
TREATMENT EFFECT ESTIMATION AND THERAPEUTIC OPTIMIZATION
USING OBSERVATIONAL DATA
In this dissertation, I address two essential questions of modern therapeutics: (1) to quantify
the effects of pharmacological agents as functions of patient’s clinical characteristics; (2) to
optimize individual treatment regimen in the presence of multiple treatment options. To ad-
dress the first question, I proposed a unified framework for the estimation of heterogeneous
treatment effect τ(x), which is expressed as a function of the patient characteristics x. The
proposed framework not only covers most of the existing advantage-learning methods in the
literature, but also enhances the robustness of different learning methods against outliers
by allowing the selection of appropriate loss functions. To cope with high-dimensionality in
x, I incorporated into the method modern machine learning algorithms including random
forests, gradient boosting machines, and neural networks, for a more scalable implemen-
tation. To facilitate the wider use of the developed methods, I developed an R package
RCATE, which is now posted on Github for public access. For therapeutic optimization, I
developed a treatment recommendation system using offline reinforcement learning. Offline
reinforcement learning is a type of machine learning method that enables an agent to learn
an optimal policy in the absence of an interactive environment, such as those encountered
in the analysis of therapeutics data. The recommendation system optimizes long-term re-
ward, while accounting for the safety of treatment regimens. I tested the method using
data from the Systolic Blood Pressure Trial (SPRINT), which included multiple years of
follow-up data from thousands of patients on many different antihypertensive drugs. Using
vi
the SPRINT data, I developed a treatment recommendation system for antihypertensive
therapies.
Wanzhu Tu, Ph.D., CoChair
Honglang Wang, Ph.D., CoChair
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Modern evidence-based medicine has been evolving in the last few decades from universal
treatment rules to individualized treatment decisions tailored to patient characteristics.
While treatment is personalized, the evidence supporting a specific therapy in a given
individual still has to come from real observable clinical data. An important source of
such data is electronic health records (EHR). We hope to distill relevant information about
various treatments from EHR and achieve certain decision rules that would guide clinical
decisions. Ultimately, these decisions have to be based on a causal understanding the
treatment effects, derived from the real treatment outcome data, usually from observational
settings.
In this dissertation, I address two practical challenges in treatment recommendation:
(1) Quantifying treatment effects in individuals of given characteristics, also known as the
heterogeneous treatment effect estimation, in situations of strong data irregularities. (2)
Selecting treatments in a dynamic therapeutic setting, by optimizing treatment outcomes
using observed data.
For the first task, one needs to effectively deal with data irregularities such as outliers
to maintain the robustness of the estimator. Additionally, a practically usable estimator
must be able to handle the high dimensionality of patient characteristics.
In the simplest situations involving only two treatments, decisions can be made by
comparing patient outcomes under the two therapies. But since the patient outcomes were
not observed under both treatments, we must consider the potential outcomes. Here, we
express the causal effect τ of a drug for a given set of patient characteristics x. We then
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compare the patient’s responses Y when the treatment is applied T = 1 and when it is not
applied T = −1. The causal effect of the drug is therefore expressed as τ(x) = E[Y (1)|X =
x] − E[Y (−1)|X = x], where Y (1) and Y (−1) are potential outcomes. The quantity τ(x)
is also known as the conditional average treatment effect (CATE). Because of the lack of
simultaneously observation of outcomes under T = 1 and T = −1, we have to operate
within a counter-factual framework, such as the one developed by Rubin and colleagues
(Rubin, 1974; Rosenbaum and Rubin, 1983).
For the single-stage problem described above, I develop a broad class of methods for
the estimation of τ(x) in the presence of data outliers and high dimensionality of x. The
robustness of the methods is gained by the incorporation of an L1-based loss function. In
comparison with the L2-based estimators, the L1-based methods drastically reduce the in-
fluences of outlying values of the data set. The estimation framework that I put forward
unites many existing estimators, including the popular efficient A-learning Robins (2004),
R-learning (Nie and Wager, 2020), inverse propensity score weighting (Horvitz and Thomp-
son, 1952; Hirano et al., 2003), augmented inverse propensity score weighting (Robins and
Rotnitzky, 1995), modified covariates method (Tian et al., 2014; Chen et al., 2017), and
modified covariates method with efficiency augmentation (Tian et al., 2014; Chen et al.,
2017) through a general estimating equation, allowing both L1 and L2-loss functions to be
employed. Theoretical properties of the proposed methods are studied to ensure the validity
of statistical inference.
I also extend the methods for τ(x) estimation from model-based estimators to algorithm-
based estimators. The incorporation of supervised learning algorithms in the estimation
process further enhances the estimators’ robustness against model mis-specification. The
automation of the analytical process also makes the methods more scalable in practical
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observational data analysis. Towards that end, I present a general-purpose R package
RCATE (https://github.com/rhli-Hannah/RCATE) for the estimation of τ(x).
The above estimators and related computational algorithms are extensively tested. As
a whole, they represent a new toolbox for causal estimation of CATE that can be used
broadly in EHR data analysis. Real data applications are presented to illustrate the use of
the proposed methods/algorithms as practical analytical tools.
For the second question of optimizing treatment in a dynamic setting, I propose a rec-
ommendation system for dynamic treatment regimens (DTR) based on patients’ responses.
I describe the development of the system within the context of hypertension treatment. Hy-
pertension is a common condition characterized by sustained blood pressure elevation. The
goal of antihypertensive treatment is to control blood pressure to the desirable range set by
the clinical guidelines (cite JNC-8), to reduce the risk of hypertension-related complications
and end-organ damage. Despite and perhaps because of the availability of a large number
of antihypertensive agents, treatment regimens are often unnecessarily complicated, with
less than optimal results.
To optimize the antihypertensive treatment, I propose a supervised batch-constrained
dueling double deep Q-network (SBC-BDQ) to help clinicians make treatment decisions that
maximize the long-term reward in blood pressure control. I choose this approach because
the standard reinforcement is known to not work well in settings of offline learning – the
data that I use to develop the system are static. Because of the large number of drugs,
and the exponentially increased number of drug combinations, exploring the full treatment
space is unrealistic. Finally, I want to make sure that the recommended treatments do not
deviate too drastically from the therapy that the treating physician has recommended for
safety and other practical reasons.
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The dissertation is structured as follows. In Chapter 2, I present the unified formu-
lation for robust estimation of CATE estimation and related theoretical properties of the
estimators. In Chapter 3, I present a scalable solution for CATE estimation by combining
the unified estimation formulation with supervised learning algorithms. In Chapter 4, I
describe a new reinforcement learning algorithm for dynamic antihypertensive treatment
recommendations. Literature reviews and methodological details concerning the proposed
methods are presented within each chapter.
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Chapter 2
Robust Estimation of Heterogeneous Treatment Effect using Electronic Health
Record Data
2.1 Introduction
The ultimate goal of precision medicine is to optimize therapeutic outcomes by tailoring
medical treatment and care provision according to individual patient characteristics. In
practice, such tailoring must be guided by causal treatment effects expressed as functions
of the observed patient characteristics x (Gabriel, 2012), which account for patient het-
erogeneity in a given clinical population. But in reality, the true treatment effect function
τ0(x) is almost never known and cannot be easily ascertained from clinical trials.
There is a sizable literature on the estimation of treatment effects in the form of τ0(x).
With covariates averaged out, τ0(x) is reduced to the average treatment effect (ATE)
τ0 =
∫
τ0(x)f(x)dx, which can be estimated from clinical trials as well as observational
studies (Imai et al., 2008). While randomized experiments provide by far the most straight-
forward estimation of τ0, valid estimates can also be ascertained from observational data,
by using the Neyman-Rubin causal model under appropriate assumptions (Sekhon, 2008).
Estimating treatment effect in the presence of heterogeneity, however, is a much involved
task. Popular approaches include the advantage or A-learning methods that directly model
the contrasts among treatments (Murphy, 2003; Robins, 2004), and the quality or Q-learners
that regress the outcomes on patient characteristics (Watkins, 1989; Watkins and Dayan,
1992). Under the general umbrella of A-learners, Tian et al. (2014); Chen et al. (2017)
described a covariate-modification method. More recently, Nie and Wager (2020) proposed
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a two-step learning algorithm that possesses a quasi-oracle property for estimating τ0(x).
Xiao et al. (2019) further improved the algorithm for enhanced robustness.
The performance of the above causal estimators is often influenced by the features of
the observed data. An attractive and readily available data source for causal inference is
EHR, digitalized medical records collected and maintained by health care organizations
(Gunter and Terry, 2005). While statisticians have long recognized the values of EHR
data in causal analysis (Stuart et al., 2013), they are also keenly aware of the challenges
presented by such data, including data outliers and high dimensionality. The former could
result in biased estimation and questionable inference, whereas the latter leads to a “curse
of dimensionality” (Donoho et al., 2000).
In this research, we address the above issues in a broader context of heterogeneous
treatment effect estimation. Specifically, we put forward a general estimation framework
based on weighted score equations. The new formulation unifies many of the existing
learners, while retaining the flexibility to accommodate different loss functions, permitting
for example robust least absolute deviation (LAD) regression. The estimating formula
enhances the capacity against outliers of modified-covariate method by Chen et al. (2017)
and extends the ability to handle higher dimensionality of robust R-learner by Xiao et al.
(2019), giving each an improvement. The approach’s direct targeting of τ0(x) relates it
nicely to the concept of the A-learning methods. We performed extensive simulation studies
to investigate the new methods’ operational performance, in comparison with the existing
ones. We also described a real data application to illustrate the use of the proposed methods.
6
2.2 Proposed Methods
2.2.1 Models and Assumptions
We consider the estimation of τ0(x), the conditional average treatment effect, within the
Neyman-Rubin potential outcome framework (Rubin, 1974). The binary treatment indi-
cator T takes values 1 or −1, i.e., T ∈ {±1}. We let Y (1) and Y (−1) be the potential
outcomes under T = 1 and T = −1, respectively. We assume that data {(Yi, Ti,Xi)}ni=1
are independent and identically distributed (i.i.d.), where the pre-treatment covariates Xi
could be high dimensional as in EHR analyses. We require the stable unit treatment value
assumption (SUTVA) (Cox, 1958; Rosenthal and Jacobson, 1968) and write the observed
outcome as Y = I(T = 1)Y (1) + I(T = −1)Y (−1), where I(·) is an indicator function.
Within this framework, we focus on
τ0(x) = E[Y
(1) − Y (−1)|X = x] = E[Y |X = x, T = 1]− E[Y |X = x, T = −1] (2.1)
= µ1(x)− µ−1(x),
where the last part comes from the ignorability assumption defined below. This makes
CATE estimation possible when X contains all confounders. When T ∈ {±1}, we can
always express the conditional mean outcome as







(1)|X = x] + E[Y (−1)|X = x]). This leads to a general interaction
model
Yi = b0(Xi) +
Ti
2
τ0(Xi) + εi, (2.2)
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where εi is subject to Assumption 3 below, along with the other assumptions stipulated by
Rubin (1974); Rosenbaum and Rubin (1983).
In the existing literature, τ0(x) is often depicted by a simple parametric model (Tian
et al., 2014; Xiao et al., 2019). With µ(x) = E[Y |X = x] = b0(x) + p(x)−12 τ0(x), one has
Yi − µ(Xi) = Ti−2p(Xi)+12 τ0(Xi) + εi, which is exactly the Robinson decomposition used by
the R-learner (Nie and Wager, 2020).










Assumption 2 (Positivity) The propensity score p(x) := P (T = 1|X = x) ∈ (0, 1).
Assumption 3 (Conditional Independence Error) The error is independent of the treat-
ment assignment conditional on covariates, i.e. {εi ⊥ Ti|Xi}. We further assume that the
conditional expectation of error exists.
2.2.2 A Unified Formulation for Heterogeneous Treatment Effect Estimation
There are two general strategies for estimating τ0(x) in (2.2). The first is to depict the con-
ditional mean function µt(x) = E[Y |X = x, T = t] with a regression model and then obtain





Yi − b(Xi;γ)− Ti2 τ(Xi;β)
)
, one can estimate β and γ simultaneously,
and then achieves a CATE estimate τ̂(x) = τ(x; β̂) (Chakraborty, 2013). Such an ap-
proach is often referred to as the Q-learning, because its objective function plays a role
similar to that of the Q or reward function in reinforcement learning (Chakraborty, 2013).
The frequently used Two- or Single-learners (T or S-learners for short) are variants of this
approach (Künzel et al., 2019).
An alternative strategy, one that we follow in the current 75 research, is to directly target
τ0(x) in a predefined objective function. This approach is often referred to as the A-learning
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(Schulte et al., 2014). A-learning first emerged in the context of dynamic treatment regime
(Murphy, 2003; Robins, 2004), and was later generalized to one-stage case for treatment
effect estimation (Tian et al., 2014; Chen et al., 2017). In this chapter, we show that there
exists a unified formulation for the objective function, written in the form of score equations,
that covers many of the existing learners.
Before introducing the general formulation, we first review the existing methods to
highlight their connections.
1. The modified outcome methods. Certain transformations of Y could be used to
facilitate the estimation of τ0(x). Estimation methods relying on such transformations
are collectively known as the modified outcome methods. This class of methods includes
the inverse propensity score weighting (IPW) (Horvitz and Thompson, 1952; Hirano et al.,
2003) and the augmented IPW (AIPW) methods (Robins and Rotnitzky, 1995). A common
feature of this class of methods is to express the true treatment effect τ0(x) as a conditional
expectation of the transformed outcome variables. For IPW and AIPW, the transformations
are
Y IPW =




T − 2p(X) + 1
2p(X)(1− p(X))
× [Y − (µ−1(X)p(X) + µ1(X)(1− p(X)))].
Writing the modified outcome as Y ∗ one has E(Y ∗|X) = τ0(X). An estimate can therefore





2. The modified covariates methods (MCM). An alternative set of methods, collectively
known as the modified covariates methods, have been derived from the model (2.2). The
central idea of this approach is to estimate τ0(X) by re-weighting the loss function instead



















whereDi = (Ti+1)/2 ∈ {0, 1}. With appropriate weighting, the minimizer of the population
version of the objective function equals to τ0(x) as elaborated in Remark 1 below. Further,
as shown in Appendix A.1, Yi can be replaced by Yi − g(Xi), where g(Xi) is an arbitrary
function of Xi. When p(Xi) =
1
2 , the variance of the estimator is minimized when we
replace Yi with Yi−µ(Xi). This is known as the modified covariates method with efficiency
augmentation (MCM-EA) (Tian et al., 2014).
3. The R-learning method. Nie and Wager (2020) recently proposed a method that they
referred to as the R-learner (RL), named after Robinson’s decomposition, a technique for
estimating the parametric components in partially linear models (Robinson, 1988). The
efficient A-learning introduced later in this section shared the same estimating equation of
the R-learner, but the two were derived from different perspectives (Robins, 2004; Lu et al.,
2013). Subtracting the marginal mean E[Yi|Xi] from the outcome, Nie and Wager worked
with the following equation









where E[εi|Xi, Ti] = 0. The treatment effect τ0(x) can therefore be estimated by minimizing











where µ(Xi) and p(Xi) are nuisance quantities estimated in advance.
Examining the relations between MCM-EA and R-learner, we note that in MCM-
EA, since E[Yi − µ(Xi) − Ti2 τ0(Xi)|Xi] 6= 0, one uses IPW as an adjustment so that
E[ Ti2Tip(Xi)+(1−Ti)
(
Yi − Ti2 τ0(Xi)
)
|Xi] = 0. In the R-learning, one has E[Yi − µ(Xi) −
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(Ti2 − p(Xi) +
1
2)τ0(Xi)|Xi] = 0, so propensity score adjustment becomes unnecessary. This
shows the difference and the connection between the R-learning and MCM-EA.
4. The A-learning (AL) methods. By directly targeting at the contrast function (treat-
























where the first term Yi − µ(Xi) − Ti−2p(Xi)+12 τ0(Xi) has mean 0 conditional on Xi. This
corresponds exactly to Robinson’s decomposition Yi−µ(Xi) = Ti−2p(Xi)+12 τ0(Xi) + εi when
E(εi|Xi) = 0. Note that Yi−µ(Xi)− Ti−2p(Xi)+12 τ0(Xi) = Yi−µ−1(Xi)−
Ti+1
2 τ0(Xi) since
µ(x) = µ−1(x) + p(x)τ(x). The µ−1(x) version was used by several authors (Schulte et al.,
2014; Tsiatis, 2019).
This shows that Nie’s R-learner shares the same conceptual essence with Robin’s efficient
A-learner, although the two were derived from different perspectives.
In summary, the methods reviewed above, including IPW, AIPW, MCM, MCM-EA, and
RL could all be viewed as variants of AL, since they all target τ0(·) directly, with the pre-
estimated plug-in nuisance quantities. We now show that these methods can be formulated
under a unified presentation of the objective functions, at the level of score equations.
Noting that the above learners are all based on solutions to some score equations cor-
responding to the objective functions under the square error loss, we specify the score







Y − T2 τ0(X)
)
;





Y − µ(X)− T2 τ0(X)
)
;





Y − µ(X)− T−2p(X)+12 τ0(X)
)
;












Y − ((1− p(X))µ1(X) + p(X)µ−1(X))− 2p(X)(1−p(X))T−2p(X)+1 τ0(X)
)
.
We note that all score equations listed above can be expressed in one general formulation
S = w(X, T )c(X, T )[Y − g(X)− c(X, T )τ0(X)], (2.4)
where the two weight functions w(x, t) and c(x, t) are subject to the following constraints
for all x and t:
C1. p(x)w(x, 1)c(x, 1) + (1− p(x))w(x,−1)c(x,−1) = 0;
C2. c(x, 1)− c(x,−1) = 1;
C3. w(x, t)c(x, t) 6= 0.
One can show that the existing estimation methods, including MCM, MCM-EA, RL, IPW,
and AIPW, are all covered by this general formulation. In Appendix A.1, we show that for
each of the above methods, the corresponding functions c and w meet the three conditions.
A few additional remarks are in order for this general expression:
Remark 1. Conditions C1-C3 are put in place to assure E(S|X) = 0. It can be shown that
under the square error loss function, the estimates derived from (2.4) are indeed minimizers
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of the target function, i.e., τ0(x) = argminτ(x)E[w(Xi, Ti)(y−g(Xi)−c(Xi, Ti)τ(x))2|Xi =
x]. For detailed proof, see Property 1 in Appendix A.2. A similar results can be obtained
under the absolute error loss function; see Property 3 in the same section of the appendix.
Remark 2. For given w(x, t) and c(x, t), one might be able to choose an appropriate g(x) to
achieve robustness to model mis-specification. For example, the g(x) = (1 − p(x))µ1(x) +
p(x)µ−1(x) in the AIPW method with equation
E
[





Ti − 2p(Xi) + 1
τ0(Xi)
) ∣∣∣∣Xi] = 0
leads to double robustness. Specifically, AIPW is robust against mis-specification of either
propensity score model or both µ−1(x) and µ1(x).
Remark 3. When an additional condition c(x, 1) = 1−p(x) holds and g(x) = µ(x), the score
equation in (2.4) leads to an estimator with the minimized variance. For an R learner, we
have c(x, 1) = 1− p(x), and the choice of g(x) = µ(x) leads to the most efficient estimator.
For MCM, this additional condition also holds when p(x) = 12 , as in the case of randomized
clinical trials.
Remark 4. With the unified formulation for the score functions, new estimators can be
derived, for example, E[(Ti− 2p(Xi) + 1)(Yi− g(Xi)− Ti2 τ0(Xi))|Xi] = 0, where g(X) is an
arbitrary augmented function of X.








w(Xi, Ti)ρ(Yi − g(Xi)− c(Xi, Ti)τ(Xi)) + Λn(τ(·)), (2.5)
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where ρ(·) is a user-specified loss function, and Λn(·) is a structural penalty function for τ(·).
This general procedure covers most of the existing methods for heterogeneous treatment
effect estimation through a unified formulation.
2.2.3 Estimation Methods under the L1 Loss
The estimation procedure described in (2.5) is general and flexible in the sense that it
allows the analyst: (1) to choose different estimators through the specification of w(·) and
c(·); (2) to select g(·) for efficiency enhancement; and (3) to specify a loss function ρ(·)
that is most appropriate for the application. This general formulation provides a natural
remedy to two practical issues in EHR data analysis: (1) lack of robustness of the L2-based
methods against outliers, (2) lack of accommodation of the high dimensionality of X, and
nonlinearity of τ(X).
Specifically, we put forward a class of robust estimators within the confines of the general
estimating function (2.5). The method accommodates nonlinearity in τ(·), further enhanc-
ing the modeling flexibility. Estimation is implemented under the usual causal inference
Assumptions 1− 3.




w(Xi, Ti) · |Yi − g(Xi)− c(Xi, Ti)τ(Xi)|
∣∣∣∣Xi = x] = τ0(x).
To increase efficiency, we opt to use g(Xi) = µ(Xi) in proposed methods.







w(Xi, Ti)|Yi − µ(Xi)− c(Xi, Ti)τ(Xi)|+ Λn(τ(·)), (2.6)
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where Λn is added to ensure sparsity at the function level. For simultaneous variable
selection and smooth estimation, we adopt a similar penalty term in (2.6) as described by
Meier et al. (2009).
We further assume an additive structure for the treatment effect function τ(·):
τ(x) = α+m1(x1) +m2(x2) + ...+mp(xp),






where {Bjk(xj)}Kn+qk=1 are the B-spline basis functions, Kn and q are number of knots and
degree.
Rewriting the spline bases and coefficients as vectors, we have τ(x) = α + βTB(x),
where B(x) = (BT1 (x1), · · · , BTp (xp))T = (B11(x1), B12(x1), · · · , B1(K+q)(x1), · · · ,
Bp(K+q)(xp))
T , β = (βT1 , · · · ,βTp )T = (β11, β12, · · · , β1(K+q), · · · , βp(K+q))T . For simplicity,
we choose a commonKn+q for all spline components. Following a suggestion ofKn 
√
n+4
by Meier et al. (2009), we use Kn =
√
n/2, which is of the same order and not too large for
implementation.




Pλ1,γ(J(mj)), with J(mj) =
√
||mj ||2n + λ2I2(mj), (2.7)








j Djβj is for variable selection in a group-wise man-
ner, and I2(mj) =
∫
(m′′j (x))








(x)dx are the (l1, l2)th entry of the
(Kn + q)× (Kn + q) matrices Dj and Ωj respectively. And Pλ1,γ(·) is the smoothly clipped
15
absolute deviation (SCAD) penalty defined by its first derivative




with γ > 2 and Pλ1,γ(0) = 0. We use γ = 3.7 as suggested by Yuan and Lin (2006).
















nDj + λ2Ωj . By decomposing Mj = R
T
j Rj for some invertible matrix





j Rj and B̃j(Xj) = R
−1
j Bj(Xj). (2.8)
With these transformations, the optimization of (2.6) becomes an ordinary least absolute














where ||β̃j || is the Euclidean norm, Y ∗i = w(Xi, Ti)(Yi−g(Xi)) and w∗i (Xi, Ti) = wi(Xi, Ti)×
|c(Xi, Ti)|. The estimation of CATE is therefore τ̂(x) = α̂+ ˆ̃βT B̃(x).
2.2.4 A Computational Algorithm
To optimize (2.9), one has to estimate µ(·) and p(·), as they are involved in the weight
functions w(x, t) and c(x, t). Herein, we use pre-estimated µ̂(·) and p̂(·) as plug-in estimates
for solving (2.9). Estimation accuracy of these quantities, however, can be impeded by the
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dimension of xi and the uncertainty of the functional forms of the xi’s associations with Ti
and Yi. To remedy, we use a gradient boosting machine (GBM) to estimate these two func-
tions (McCaffrey et al., 2004), with packages gbm (Ridgeway and Ridgeway, 2004) and caret
(Kuhn, 2012). In cases of ultra-high dimensional xi, one could first use non-parametric in-
dependence screening (NIS) method (Fan et al., 2011) to reduce the dimensionality to a
moderate one (n − 1 or log(n)) as suggested by Fan and Lv (2008)), before applying our
proposed method.
With the plug-in estimates of µ(·) and p(·), we solve the L1 optimization problem in
(2.9), by using R package rqPen (Sherwood and Maidman, 2016), which is designed for
penalized quantile regression in general. The nonconvex group penalized optimization with
quantile loss is solved by the extension of quantile iterative coordinate descent (QICD)
algorithm proposed by Peng and Wang (2015). For comparison purposes, we also use R
package oem (Xiong et al., 2016) to ascertain the L2 estimators.
The main steps of the procedure are described in Algorithm 1.
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Algorithm 1: Robust model-based CATE estimating algorithm
1 Input: Outcome Y , treatment assignment T , and pre-treatment covariates X
2 Data screening: Screen covariates with NIS when in situations of ultra-high
dimension;
3 Nuisance quantity estimation: Estimate p(x) by using GBM with
cross-validation (CV) and estimate µ(x) by using L1-based GBM with CV;
4 Data transformation: Construct the B-spline design matrix B(X), calculate
w(Xi, Ti), c(Xi, Ti), and g(Xi) following Conditions C1-C3, and transform B(X)
to B̃(X) using (2.8);
5 Optimization: Solve penalized LAD regression (2.9) with a group SCAD penalty
to achieve estimates of α and β̃ with regularization parameters selected by CV.
6 Output: Calculate τ̂(x) = α̂+
ˆ̃
βT B̃(x).
2.3 Asymptotic Properties of τ̂(x)







w(Xi, Ti)ρ(Yi − g(Xi)− c(Xi, Ti)τ(Xi)), (2.10)
where ρ(·) is a loss function that is convex and has unique minimizer at origin. This simpli-
fication will not diminish the contribution of the asymptotic analysis, which is complicated
by the B-spline approximation and the various loss functions including the L1, L2, Huber,
and Bisquare loss functions.
With a B-spline approximation, we write τ(x) :=
∑Kn+q
k=1 βkBk(x) = B(x)
Tβ, where q
is the degree of the B-splines and Kn is the number of knots, which we assume depending
on sample size n. Zhou et al. (1998) provided the L∞ approximation error for B-splines.
In particular, with τ∗(x) := B(x)Tβ∗ as the best L∞ approximation to the true function
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τ0(x), it satisfies
supx∈(0,1)|τ∗(x)− τ0(x)− ba(x)| = o(K−(q+1)n ), (2.11)
where





n (q + 1)!
Kn∑
k=1






with {κk}Knk=0 are the knots in the B-spline approximation, τ
(q+1)
0 (x) is the (q + 1)th order
derivative of τ0(x), and Brq(x) is the q-th Bernoulli polynomial.
We focus on the asymptotic theory of the L1 spline estimator τ̂(x) = B(x)
T β̂, where





w(Xi, Ti)ρ(Yi − g(Xi)− c(Xi, Ti)B(Xi)Tβ). (2.12)
The error for τ̂(x) can be decomposed as a summation of the estimation error and approx-
imation error
τ̂(x)− τ0(x) = τ̂(x)− τ∗(x)︸ ︷︷ ︸
estimation error
+ τ∗(x)− τ0(x)︸ ︷︷ ︸
approximation error
= τ̂(x)− τ∗(x) + ba(x) + o(K−(q+1)n ).
We only need to study the estimation error τ̂(x) − τ∗(x) = B(x)T (β̂ − β∗) thanks to the
L∞ approximation result by Zhou et al. (1998).
To show a pointwise asymptotic normality of
√
an(τ̂(x) − τ∗(x)) with a convergence
rate an to be specified later in Appendix A.3, we only need to prove the convergence of
√
an(β̂ − β∗) since τ̂(x)− τ∗(x) = B(x)T (β̂ − β∗). For this, denote δ =
√




















where Ui = Yi− g(Xi)− c(Xi, Ti)B(Xi)Tβ∗. Then the minimizer δ̂n of Un(δ) is simply our
target, i.e., δ̂n =
√
an(β̂ − β∗).
If one regards {Un(δ)} as a sequence of random functions and the finite-dimensional
distributions of Un(δ) converge in distribution to those of some random function U(δ)
which has a unique minimum, then it will follow that δ̂n =
√
an(β̂−β∗)→d argmin(U(δ)),
as n→∞ per Hjort and Pollard (1993), and Geyer (1996).
With a given loss function ρ(·), we define Φ(s|X = x, T = t) = E[ρ(Y − g(x) −
c(x, t)B(x)Tβ∗ − s)|X = x, T = t]. Let Φ′(s|X = x, T = t) and Φ′′(s|X = x, T = t)
be the first and second derivative of Φ(s|X = x, T = t) with for δ̂n; respect to s. Several
additional conditions are required for the proof of asymptotic normality:
C4. X is distributed as Q(x) on a compact set in R. Without loss of generality, we assume
X ∈ [0, 1].
C5. The B-spline knots are equidistantly located as κk = k/Kn, k = 0, ...,Kn and the
number of knots satisfies Kn = O(n
1/(2q+3)).
C6. The true CATE τ0(x) is (q + 1)th order continuously differentiable.
C7. The function ρ(u) is convex, it has a unique minimizer at zero, and its first and second
derivatives exist.
C8. For x ∈ [0, 1] and t ∈ {±1}, E[ρ′(Y − g(X)− c(X,T )τ0(X))2|X = x, T = t] <∞.
C9. Φ(s|X = x, T = t), Φ′(s|X = x, T = t), and Φ′′(s|X = x, T = t) are functions of s
and they are bounded and continuous in a neighborhood of zero.
C10. As s→ 0, E[{w(X,T )
(
ρ (U − s)− ρ(U)− ρ′(U)s
)
}2] = o(s2).
C11. There exists a γ > 0 such that for any x ∈ [0, 1] and t ∈ {±1},
E[|w(X,T )c(X,T )ρ′(U)|2+γ |X = x, T = t] <∞.
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Remark 5. The above conditions are needed for establishing an asymptotic normality of the
estimator. Conditions C4-C6 are standard assumptions for B-spline regression. C5 provides
the appropriate conditions of the knots. It suggests that the locations of the knots are set
to some extent at regular intervals and the number of knots increases with the sample
size. C4-6 are needed for controlling the spline approximation bias. C7-C8 are the general
conditions for the loss function. The commonly used L1, Huber, and Bisquare loss functions
for robust regression all satisfy these conditions. C7 also guarantees the uniqueness of the
estimator. C9 and C10 ensure the smoothness of the loss function ρ, which are needed for
controlling the remainder term in the Taylor expansion. C11 is needed for satisfying the
Lyapunov condition of the Central Limit Theorem.
To describe the asymptotic normality of the spline estimator τ̂(x), we introduce two













where ν(x) = p(x)w(x, 1)c(x, 1)2ρ′′(y(1) − g(x)− c(x, 1)B(x)Tβ∗) + (1− p(x))w(x,−1)
c(x,−1)2ρ′′(y(−1) − g(x)− c(x,−1)B(x)Tβ∗).
Theorem 1 Assuming C1-C11, as n → ∞, we have
√
n/Kn(τ̂(x) − τ0(x) − ba(x))
D→




Remark 6. With the order of Kn larger than O(n
1
2q+3 ), the B-spline approximation error
ba(x) can be ignored relative to the order of its variance.
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For the rest of the chapter, we focus on the LAD loss where Conditions C7-C10 are
naturally satisfied, and C11 can be simplified as the following:
C12. There exists a constant γ ≥ 0 such that E
{
|w(X,T )c(X,T )|2+γ |X = x
}
<∞.
To describe the asymptotic normality of the spline estimator τ̂(x) under the L1 loss, we





p(x)w(x, 1)c2(x, 1)f1(g(x) + c(x, 1)τ0(x)|x)
+ (1− p(x))w(x,−1)2c(x,−1)f−1(g(x) + c(x,−1)τ0(x)|x)
]
Bi(x)Bj(x)dQ(x),
where f1(y|x) and f−1(y|x) are the conditional density functions of Y (1) and Y (−1) given
X = x, respectively. We give the following theorem for the spline-based LAD regression:




D→ N(0,Ψ(x)), where Ψ(x) = limn→∞ 14KnB(x)
TD−1GD−1B(x).
Remark 7. For inference concerning τ0(x), the variance of the estimator can be obtained
by using resampling methods, as the asymptotic variance is difficult to work with. In a
simulation experiment in Appendix A.4, we show that the bootstrap C.I. consistent with
theoretical C.I..
2.4 A Simulation Study
We conducted an extensive simulation study to evaluate the finite sample performance of
the proposed methods. We considered a large number of parameter settings, including four
different learners under two different loss functions: (1) a robust version of the modified
covariate method with efficiency augmentation (L1-MCM-EA), (2) a robust R-learner (L1-
RL), (3) a robust A-learner (L1-AL), (4) an L2-based MCM-EA, (5) an L2-based RL, (6) an
L2-based AL, and (7) a robust Q-learner (L1-QL), and (8) an L2-based Q-learner (L2-QL).
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The first six methods are under the umbrella of A-learning and they are covered by the
general formulation in (2.5). The last two are Q-learning methods, which are not the focus
of the current chapter; we included them only for comparison. The first three methods are
what we recommend for situations with a significant number of outliers; Methods 4-6 are
standard L2-based learners.
We used the A-learner described by Lu et al. (2013). The objective functions of the


















where γ and p(x) are estimated in advance. We estimated γ by regressing Y on X using a
linear regression, and p(x) by regressing T+12 on X using GBM. The objective functions of















where we used L1 or L2 loss function for ρ. Note that a difference between the A-learner
and R-learner is the choice of the augmentation. For A-learner we used a linear function as
suggested by Lu et al. (2013) to estimate µ(Xi); we used L1-based GBM to estimate µ(Xi)
in the R-learner.
We designed the simulation study to assess the robustness of the L1 and L2-based
methods, and to contrast the performance of the A and Q-learners. We also examined the
performance of the methods under different sample sizes, dimensionality, and proportions
of outliers.
We assessed the performance of the methods using the standard metrics, including bias,
variance, mean square error as well as mean absolute error. In addition, we compared the
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value function Q(η̂) = E(Y (η̂)), i.e., the expected average outcome under treatment η̂,
where η̂(x) = 2I(τ̂(x) > 0) − 1, as recommended by each method (Zhang et al., 2012).
To estimate the Q(η̂) for a given regimen, we conducted a Monte Carlo simulation using
model Y (η̂) = b0(X) +
η̂
2τ0(X) + ε, replacing T in (2.2) by η̂, and we set the number of
replicates is 106. The value function calculated based on the true treatment effects was
E[Y (ηopt)] = 1.25, where ηopt(x) = 2I(τ0(x) > 0) − 1. We also assessed the sensitivity
and specificity for variable selection under our penalty. With the number of simulation






























where xv is the v-th observation from the validation set, τ̂
(r)(x) is the estimator of τ(x)
based on the r-th data replication, and τ̂(xv) is the average of all estimators of the v-th
observation. TP, FN, TN, and FP represented the numbers of true positive, false negative,
true negative, and false positive. In this research, the size of the validation set nv was set to
200; we summarized the performance over the whole validation set by taking the averages
(i.e.,MSE = 1nv
∑nv
v=1MSEv). For simplicity, we reported MSE, MAE, |Bias|2, and V ar.
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2.4.1 Data Generation
We generated data as follows, the dimension of the covariates was indexed by p:
Xi ∼ Np(0,Σ), diag(Σ) = 1, Corr(Xij , Xik) = 0.5|j−k|, i = 1, ..., n,
Di|Xi ∼ Bernoulli(p(Xi)), Ti = 2Di − 1, logit(p(Xi)) = Xi1 −Xi2,
Yi = b0(Xi) +
Ti
2
τ0(Xi) + εi, εi ∼ (1− ξo)N(0, 1) + ξoLaplace(0, 10),
b0(Xi) = 0.5 + 4Xi1 +Xi2 − 3Xi3, τ0(Xi) = 2sin(2Xi1)−Xi2 + 3tanh(0.5Xi3),
where ηo represented the proportion of outliers. We considered three settings: (1) Various
levels of outliers ξo ∈ {0, 0.05, 0.1, 0.15, 0.2}, with n = 1000 and p = 10; (2) Various training
sample sizes n ∈ {200, 500, 1000}, with p = 10 and ξo ∈ {0, 0.05}; (3) Various dimension of
training sample p ∈ {10, 30, 50}, with n = 1000 and ξo ∈ {0, 0.05}.
2.4.2 Simulation Results
Figure 2.1 showed that when there were outliers, the L1-based methods uniformly outper-
formed the L2-based methods under the MSE, MAE, and Q(η̂) value. Advantage of the
robust methods increased with the proportion of outliers. The robust R-learner outper-
formed the robust A-learner because µ(x) was not a linear function. And there were little
practical differences between the robust R-learner and robust MCM-EA. The Q-learner per-
formed the best under MSE and MAE because it is a one-step estimation procedure, and
thus avoiding the errors associated with the nuisance quantity estimation. This is consistent
with the observations made by Schulte et al. (2014) that the Q-learner tended to perform
better than the standard A-learner when all models were correctly specified. We conducted
a separate simulation for a setting where the Q-function was mis-specified. The results
reported in Appendix A.5 showed that in the presence of outliers, bias in the mis-specified
L1-QL was larger than that of the L1-MCMEA, L1-RL, and L1-AL. The same was also true
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for MSE and MAE. In terms of the value function Q(η̂), L1-QL had smaller Q(η̂) values
than methods under the A-learning umbrella; findings were consistent with MSE.
Figure 2.1: Simulation results of Setting 1.
Note: Comparison of mean squared error (MSE), mean absolute error (MAE),
and value function (Q(η̂)) of the L1-MCM-EA (red solid line), L1-RL (red solid
line), L1-AL (red solid line), L1-QL (red dashed line), MCM-EA (black solid
line), RL (black solid line), AL (black solid line), and QL (black dashed line)
under various levels of outliers. When there were outliers, both L1-based meth-
ods outperformed the L2-based methods. Advantage of the L1-based methods
increased with the proportion of outliers, under MSE, MAE, and Q(η̂).
Figure 2.2 (A-D) showed the effects of sample size. Regardless of the presence or ab-
sence of outliers, as the sample size increased, MSE and MAE decreased for all methods.
When there were no outliers, at a given sample size, the L2-based methods tended to per-
form slightly better than the L1-based methods, because the L2-based methods were more
efficient when the errors were normally distributed. But when there were even a small
proportion of outliers, only 5% of errors generated from a different distribution, the robust
methods outperformed L2-based methods by a noticeable margin. Figure 2 (E-H) showed
that the performance of proposed methods without NIS did not change substantially as the
dimension of the covariates increased.
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Figure 2.2: Simulation results of Setting 2
Note: Panels A-D – Mean squared error (MSE) and mean absolute error (MAE)
values of different methods under different sample sizes, with and without out-
liers. The L1-based methods are indicated by red symbols, whereas the L2-based
methods are indicated by black symbols. Panels E-H – Impact of the dimen-
sion on different methods. L1-based methods (red lines) are robust to outliers,
whereas the L2-based methods (black lines) are standard methods.
Additional simulation details, including the squared bias, variance, MSE, MAE, sensitiv-
ity, specificity, and value function of the eight methods were reported in Appendix A.5. We
have also examined the effects of dimension and smoothing on treatment effect estimation.
Those results are included in Appendix A.5.
We conducted additional simulation in one covariate setting, where we calculated the
pointwise bootstrap confidence intervals for τ(x), under both L1 and L2 versions of the
MCM-EA and RL methods, with and without penalty. The L1-based methods generally
produced coverage probabilities very close to the nominal level, even with the presence of
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outliers, whereas the L2-based methods’ coverage sometimes deviated strongly from 0.95.
See Appendix A Table A.5.
2.5 Real Data Application
To illustrate the methods we propose, we estimated the treatment effects of two different
antihypertensive therapies by analyzing the observed clinical data set from the Indiana Net-
work of Patient Care, a local EHR system. The data were a subset of a previous study
assessing the blood pressure (BP)-lowering effects of various antihypertensive agents (Tu
et al., 2016). This analysis compared the BP effects of angiotensin-converting-enzyme in-
hibitors (ACEI) alone and a combination of ACEI and hydrochlorothiazide (HCTZ). We
considered those on ACEI alone as in treatment group A, and those on ACEI+HCTZ as
in group B. The primary outcome of interest is clinically recorded systolic BP in response
to these therapies. Independent variables included the demographic and clinical charac-
teristics, as well as medication-use behaviors of the study participants. Data from 882
participants were used in the current analysis. Among these, 350 were on the monotherapy
of ACEI, and 532 were on the combination therapy of ACEI+HCTZ. Characteristics of the
study participants are presented in Table 2.1. There were 4 continuous variables (pulse,
BMI, age, and medication adherence) and 12 binary variables (gender, race, and ten comor-
bidities). The continuous variables were standardized before the analysis and expressed as
linear combinations of splines.
We expressed the treatment effect of treatment B, in comparison against treatment A,
as a function of the patient characteristics x
τ0(x) = E[Y
(B) − Y (A)|X = x],
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where Y (A), Y (B) represented the potential systolic BP of ACEI alone group and ACEI+
HCTZ group. Since the antihypertensive effect of a therapy is measured by its ability to
lower BP, a negative τ(x) indicates a superior effect of the combination therapy over the
monotherapy, for a given x. An important covariate of interest was the level of medica-
tion adherence, which we measured with the proportions of days covered (PDC) by the
medication.
Preliminary data examination showed that the observed systolic BP was right-skewed
in both groups. The Shapiro–Wilk’s test further confirmed that the systolic BP was not
normally distributed, and there were outliers in the observed outcome (ACEI alone: W =
0.9912, p = 0.035; ACEI+HCTZ: W = 0.9617, p = 1.498e − 10). See Appendix A.6. We,
therefore, used the L1-based methods with additive B-splines to analyze the data. Here the
B-splines were used to accommodate the possible nonlinear influences of the independent
variables on the treatment effect.
Naive comparison of the systolic BP-effects between the two treatment strategies sug-
gested that the combination therapy (ACEI+HCTZ) was significantly worse than the monother-
apy (ACEI alone) in its ability to lower systolic BP (Table 1, 134.86mm Hg in ACEI vs.
137.49 mm Hg in ACEI+HCTZ; p = 0.004). A similar difference was seen in diastolic
BP (80.98mm Hg in ACEI vs. 82.26 mm Hg in ACEI+HCTZ; p = 0.046). The obser-
vation is counterintuitive because there are no known mechanisms that would explain the
attenuated BP benefit of ACEI when HCTZ is added to the treatment regimen. In fact, the
current clinical guidelines recommend HCTZ as the first-line therapy for essential hyperten-
sion James et al. (2014). BP is regulated by hormones in the renin-angiotensin-aldosterone
system (RAAS) (Tu et al., 2017). ACE inhibitors block the conversion of angiotensin I
to angiotensin II, diminishing the latter’s effects on aldosterone production and sodium
retention and causing BP reduction. Thiazide diuretics lower BP by suppressing the extra-
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cellular fluid volume, which in turn reduces aldosterone secretion. Together, the two drugs
are expected to have additive effects in lowering BP. In clinical practice, the two are often
used concurrently.







Average Systolic BP 134.86 (11.72) 137.49 (14.11) 0.004*
Average Diastolic BP 80.98 (8.64) 82.26 (9.77) 0.046*
Pulse 83.67 (10.36) 81.12 (10.51) <0.001*
BMI 31.75 (8.65) 33.39 (8.79) 0.007*
Age 47.83 (12.84) 50.03 (12.43) 0.012*
Medication Adherence (PDC) 0.45 (0.30) 0.52 (0.27) <0.001*
n (percentage)
Male 158 (45.1%) 189 (35.5%) 0.005*
Black 144 (41.1%) 290 (54.5%) <0.001*
Diabetes 155 (44.3%) 114 (21.4%) <0.001*
Chronic Kidney Disease (CKD) 8 (2.3%) 13 (2.4%) 1.000
Coronary Artery Disease (CAD) 10 (2.9%) 15 (2.8%) 1.000
Myocardial Infraction (MI) 2 (0.6%) 3 (0.6%) 1.000
Congestive Heart Failure (CHF) 7 (2.0%) 11 (2.1%) 1.000
Hyperlipidemia 53 (15.1%) 88 (16.5%) 0.645
Atrial fibrillation 1 (0.3%) 5 (0.9%) 0.461
Stroke 9 (2.6%) 6 (1.1%) 0.175
Chronic Obstructive Pulmonary Disease (COPD) 40 (11.4%) 51 (9.6%) 0.443
Depression 88 (25.1%) 132 (24.8%) 0.975
A closer examination of the characteristics of the patients on these therapies showed that
patients on the combination therapy were older, more likely to be female, and overweight.
Using GBM described in Section 2.3, we examined the mean function of systolic BP µ̂(x)
and the propensity of a patient receiving the combination therapy p̂(x). The estimated
propensity score distributions were clearly different for the two treatment groups, whereas
the mean functions were similar. See Appendix A.7. More specifically, the histogram of
mean functions overlapped, indicating no apparent differences between the mean systolic
BP between the two treatment groups. The different propensity score distributions of the
two groups clearly showed that non-random treatment assignment. The importance levels
of the covariates from GBM and additional modeling details were summarized in Appendix
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A.7. The systematic differences in patient characteristics between the two treatment groups
suggested that a naive comparison was not appropriate and should not be trusted.
We then analyzed the data with the proposed methods. Importantly, both the L1-MCM-
EA and L1-RL selected BMI and PDC in the final models. The L2-based methods, on the
other hand, only selected PDC. As we have shown in the simulation study, in the presence
of outliers, the rates of correct selection of patient characteristics in the proposed methods
were substantially greater than that of the L2-based methods. The estimated treatment
effects as functions of BMI and PDC were depicted in Figure 2.3.
Figure 2.3 showed that τ̂ gradually decreased as the medication adherence measure
PDC increased. Lower τ̂ indicated a stronger efficacy of the combination therapy than
the monotherapy. Although decreasing trends were observed in both L1 and L2-based
methods, the L2 methods failed to detect any differences between the two therapies, as the
95% confidence intervals for τ̂(PDC) consistently covered zero. The L1-based estimators,
however, showed a superior blood pressure-lowering effect of the combination therapy, but
only when PDC> 90%. The fact that treatment effects varied with medication adherence
should not be surprising. As the former US Surgeon General, Dr. C. Everett Koop, wisely
observed, “Drugs don’t work in patients who don’t take them.” Osterberg and Blaschke
(2005) In this analysis, we do not expect significant differences between the treatments when
patients are not adherent to the prescribed regimen. Findings such as this are not unexpected
in comparative effectiveness analysis of EHR data. Because unlike well-controlled clinical
trials, few measures are in place to ensure patients faithfully take their medications in the
real-world of clinical care. In the current application, the fact that the L1-based estimators
detected significant differences highlights the proposed methods’ advantage. Using L1-based
estimators, we also examined the influences of BMI on τ , which did not reach the level of
statistical significance (data not shown).
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Figure 2.3: Marginal treatment effect of PDC
Note: Estimated treatment effects as functions of medication adherence
(Proportion of Days Covered or PDC) under different methods. To plot
these marginal effects, we fixed the continuous covariates at their mean
values, and binary covariates at zero.
To check the conditional independence error assumption, we performed the invariant
residual distribution test (IRD-test), invariant environment prediction test (IEP-test), in-
variant conditional quantile prediction test (ICQP-test), invariant targeted prediction test
(ITP-test) Heinze-Deml et al. (2018), and invariant residual prediction test (IRP-test) (Shah
and Bühlmann, 2018). The conditional independence error assumption held for both pro-
posed methods at the significant level of 0.05.
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Table 2.2: Conditional independence test results
Method IRD-test IEP-test ICQP-test ITP-test IRP-test
L1-RL 0.11 0.71 0.82 0.58 0.26
L1-MCM-EA 0.25 0.71 1.00 0.57 0.20
Note: The values in the table are p-values. The conditional in-
dependence error assumption holds for both proposed methods
at the significant level of 0.05.
In addition to the marginal treatment effect, we also examined the value function Q̂(η̂),
which is the expected SBP under the estimated treatment regime η̂(x) = 2I(τ̂(x) < 0)− 1.
In the absence of a true value function, we used a 10-fold cross validation to estimate Q̂(η̂).
For each fold Fj , we used the rest data for estimating µ̂
(−j)(x), p̂(−j)(x), and τ̂ (−j)(x).






(−j)(xi) < 0) − p̂(−j)(xi)]τ̂ (−j)(xi). By looping over j = 1, 2, ..., 10, we
calculated Q̂(η̂) = 110
∑10
j=1 Q̂
(j)(η̂). The observed average SBP was 136.45 mmHg, the
estimates based on the L1-MCMEA and L1-RL were lower than the observed value. The
estimates based on L2-MCMEA and L2-RL were slightly higher than the corresponding L1-
based methods. This results showed that the SBP could be reduced if treatment were to be
assigned in accordance with the therapy recommended by the estimated treatment regime.
Table 2.4 showed among the patients included in the analysis, 100 (11.3%) had PDC above
90%. We further examined the numbers of patients assigned to the two different treatment
groups based on the estimated treatment effects. More patients would be assigned to the
combination therapy group because it had a significantly greater blood pressure efficacy
when patients take their medications. On the other hand, had we used the L2 based
methods, almost all of the patients would have been assigned to the monotherapy group,
which contradicts the recommendations from the current clinical guidelines.
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Table 2.3: Value functions of methods considered in application
Method L1-RL L2-RL L1-MCM-EA L2-MCM-EA
Q̂(η̂) 134.98 135.13 133.96 134.64
Note: The value function is the expected systolic blood pressure under the esti-
mated treatment regimen η̂(x) = 2I(τ̂(x) < 0)−1. Differences in value functions
of the L1 and L2-based methods are minimal. However, the L1-based methods
outperform the L2-based methods when data irregularities are present. See re-
sults from Table 2.4 and Figure 2.3.
Table 2.4: Treatment Assignment of Observations with PDC > 0.9
Method Monotherapy (n) Combination Therapy (n)





Note: Patients in the application data set whose
PDC > 0.9 are reassigned treatments by estimated
treatment effect, i.e. η̂(x) = 2I(τ̂(x) < 0) − 1. Un-
der the L1-based methods, most of the patients will be
assigned to the combination therapy group, consistent
with the results in Figure 2.3. However, under the L2-
based methods, most of the patients will be assigned to
the monotherapy group, which is counter-intuitive, be-
cause when patient adhere to prescription, the combi-
nation therapy is known to be more efficacious.
In summary, the naive and L2-based methods showed that the combination therapy of
ACEI and HCTZ had a worse BP-lowering effect than the monotherapy of ACEI, a finding
that contradicts the recommendations of the current clinical guidelines of hypertension
treatment. The L1-based methods have produced results that are better explained by the
existing clinical and biological evidence. The analysis showed that treatment effects tended
to improve when patients adhere to their prescribed medications.
2.6 Discussion
We started this work searching for a robust estimator for heterogeneous treatment effects
that could be used in EHR analysis, where outliers often undermine the validity of esti-
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mation. In the process, we discovered a general formulation that not only addresses the
issues of outliers but also covers a broad class of learners, including the commonly used A-
learner, as well as other learning methods associated with it, such as the inverse propensity
weighting, various modified outcome methods, modified covariate methods with or without
efficiency augmentation, and the doubly robust method. Through a clever specification of
the weight and efficiency augmentation functions, the formulation not only brings together
a diverse set of methods under a unified presentation but also facilitates the development
of a general-purpose implementational procedure. Although we have highlighted the use of
the L1 loss function for increased robustness against outliers in the EHR data, the score
equation we described can readily accommodate other loss functions, giving the analyst
much-enhanced flexibility in practical data analysis. As we have shown in our simulation
studies, the use of L1 loss function in heterogeneous treatment effect estimation substan-
tially increases the estimation methods’ robustness. Importantly, the gain in robustness
does not appear to inflict a heavy toll on efficiency. Initial theoretical exploration sug-
gests that reasonable asymptotic behavior can still be expected for the resultant estimators
under various loss functions. Besides the flexibility in loss function selection, the general
formulation also permits the incorporation of other useful features, such as nonparametric
specifications of the mean and propensity functions and embedded dimensional reduction
tools.
A theoretical examination of the proposed method shows that the resultant estimators
possess the desirable property of asymptotic normally, under fairly general regularity con-
ditions, and various commonly used loss functions. Simulation studies have provided strong
and consistent empirical evidence on the utility of the proposed methods. Then through a
real data application, we demonstrated how the proposed approach could be used in EHR
data analysis to quantify treatment effects that varied with patient drug-taking behaviors.
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The findings are in line with the existing clinical understanding of the therapeutic effects
of the treatments. This said, the proposed method’s performance remains to be tested in
a wider range of clinical applications. Notwithstanding this limitation, we have taken the
first steps in developing a scalable solution to estimate heterogeneous treatment effects in
settings that are more prone to various forms of data irregularities.
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Chapter 3
Algorithm-based Robust Estimation of Heterogeneous Treatment Effects
3.1 Introduction
In causal analyses of observational data, analysts face practical challenges in both methodol-
ogy and implementation: (1) While there is a large literature on estimating treatment effects
in observational studies, few methods are designed to deal with data irregularities and high
dimensionality. Failure to accommodate these data characteristics tends to undermine the
validity of causal estimation and inference. (2) Model-based causal inference methods are
also vulnerable to model mis-specification, which could lead to erroneous conclusions. (3)
For implementation, few software packages are available for use in an off-the-shelf fashion.
Lack of ready-made analytical tools hinders practical use of innovative methods because
practitioners are rarely in a position to implement and test complicated causal inference
methods for practical data analyses.
In this research, we address the above challenges by putting forward a new set of tools
to aid practical causal analysis of observational data. The tool kit includes a new class of
estimators that we have recently developed for heterogeneous treatment effects (see Chapter
2). The methods are robust against data irregularities such as outliers, and they are also
designed to handle high dimensional data, such as those encountered in electronic health
records. We further extend the model-based estimators to algorithm-based methods to
reduce the risk of model mis-specification. The supervised learning algorithms used in the
estimating process enhance the methods’ general usability and free analysts from the tedious
model-fitting process. Finally, we implement these causal inferences tools in the form of
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an R package - RCATE, which stands for Robust Estimation of the Conditional Average
Treatment Effects.
For narrative convenience, we describe the development of estimation methods and
related analysis tools in the context of treatment effects comparison of two antihypertensive
therapies, by using the same real electronic health record data as Section 2.5. The chapter
is structured as follows: In Section 3.2, we introduce the notation and assumptions for
the estimation procedure. In Section 3.3, we present a simulation study to verify the
performance of the proposed methods. In Section 3.4, we revisit the antihypertensive study
and present the analytical results. Finally, we summarize our findings in Section 3.5. Details
of the R package RCATE are provided in Appendix B.1.
3.2 Methods
3.2.1 The existing methods
There is a sizable literature on the estimation of CATE using observational data. Caron
et al. (2020) and Zhang et al. (2020) provided reviews of state-of-the-art methods for CATE
estimation. We summarize the key features of the existing methods in Table 3.1, which
also provides the availability of analytical software. Importantly, most of these methods are
based on the L2-loss function, whose performance tends to deteriorate with data irregularity.
More recently, our research team developed a general formulation that has unified dif-
ferent learners (see Chapter 2). The formulation also accommodates other loss functions
including L1-loss, Huber loss, and Bi-square loss that enhance the estimators’ robustness
against data irregularities. In the next section, we briefly review this general formulation,
and its coverage of the existing methods.
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Table 3.1: Summary of existing popular CATE estimation algorithms
Base-learner/








(+) If the treatment effect is
simple, then pooling the data
together will be beneficial.
(–) Performs bad if the treatment
effect is strongly heterogeneous
and the response surfaces of two




Fits two models for the
outcome of two treatment
groups separately
with the covariates.
(+) Performs well if the
treatment effect is strongly
heterogeneous and the response
surfaces of two groups are very
different.





A three step approach to
crossover the information
in the control and treated
subjects.
(+) Has the advantages of both
S and T-learner.
(–) The three-step estimator
increases the risk of







score weighting, then the
conditional expectation of
the transformed outcome
is the treatment effect.
(+) After transformation, the
IPW provides the flexibility in
choosing off-the-shelf supervised
learning algorithms.
(–) Relies on the accurate
estimation of the propensity
score.
AIPW
Augmented IPW is robust
to mis-specified mean or
propensity score model.
(+) In addition to the advantage





by subtracting the mean
model and gets an
estimating equation.
(+) In addition to the advantage






to get an estimating
equation.
(+) Same as IPW.
(–) Relies on the accurate





model and the slope is
the treatment effect
function.
(+) No nuisance parameter need
to be estimated.
(–) Lacks of flexibility in




Uses regression tree that
splits by maximizing the
difference between
treatment effects in child
nodes to fit the outcome.
(+) Easy to interpret and
provides the grouping of
subjects.







to build causal trees, then
aggregate the results.
(+) Addresses the high variance
problem.
(–) Lose the interpretability.
grf
Causal boosting
(Powers et al., 2018)
An adaption of gradient
boosting algorithm with
causal trees as weak-
learner.
(+) Well-tuned causal boosting
outperforms the causal forest.
(–) Takes longer to train than




ers et al., 2018)
Fits two multivariate
adaptive regression
spline models in parallel
in two arms of the data.
In each step, it chooses
the same basis function to
add to each model.
(+) Alleviates the bias problem
of tree-based algorithms because
they use the average treatment
effect within each leaf as the
prediction for that leaf.
causalLearning
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3.2.2 A unified formulation for heterogeneous treatment effect estimation







w(Xi, Ti)M{Yi − g(Xi)− c(Xi, Ti)τ(Xi)}, (3.1)
where M(·) is a user-specified loss function, and the two weight functions w(x, t) and c(x, t)
are subject to three constraints C1-C3. In Table 3.2, we list the functions c, w, and g that
can be chosen to meet the constraints for popular A-learning methods.
Table 3.2: Parameters of some popular methods in the framework
Method w(Xi, Ti) g(Xi) c(Xi, Ti)
MCM {Tip(Xi) + (1− Ti)/2}−1 0 Ti2
MCM-EA {Tip(Xi) + (1− Ti)/2}−1 µ(Xi) Ti2













(1− p(Xi))µ1(Xi) + p(Xi)µ−1(Xi) 2p(Xi)(1−p(Xi))Ti−2p(Xi)+1
In practice, the existence of outliers is common and L1-loss based methods can naturally
alleviate the impact of data irregularities and lead to a robust estimation. With an L1-loss
function, under Conditions C1-C3,




w(Xi, Ti) · ‖Yi − g(Xi)− c(Xi, Ti)τ(Xi)‖1
∣∣Xi]. (3.2)
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3.2.3 Supervised learning algorithms for robust CATE Estimation
Through a transformation, CATE estimation in (2.6) becomes a problem of ordinary least






w∗i (Xi, Ti)|Y ∗i − τ(Xi))|, (3.3)
where Y ∗i =
Yi−g(Xi)
c(Xi,Ti)
and w∗i (Xi, Ti) = wi(Xi, Ti)|c(Xi, Ti)|. F depends on the algorithm
one uses, the algorithms can also take care of variable selection in high dimensional sit-
uations. In Section 3.3, we compare the L1 and L2-based algorithms. For the L2-based
methods, the transformed weight is w∗i (Xi, Ti) = wi(Xi, Ti)c(Xi, Ti)
2.
With the objective function in (3.3), different supervised learning algorithms can be used
to estimate CATE - the optimization becomes a weighted supervised learning problem,
where Y ∗i and w
∗
i are the new outcome and new weight of each sample. The nuisance
quantities in Y ∗i and w
∗
i are pre-estimated and plugged in. Similarly, any supervised learning
algorithm with weighted L1 loss can be used with (3.3) to achieve robust CATE estimation.
In this section, we describe three different algorithms for this purpose. The algorithms are
based on Random Forests (RF), gradient boosting machine (GBM), and artificial neural
network (ANN). The common process underlying these algorithms is depicted in Figure 3.1.
The detailed algorithms are introduced in following subsections.
Figure 3.1: The estimating process of proposed algorithms.
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Robust Random Forest Learner
We first used RF for robust treatment effect estimation. The building blocks of random
forests are regression trees (Breiman et al., 1984), which recursively partition the sample by
covariates to minimize the heterogeneity in the outcomes. The partition that minimizes the
heterogeneity in child nodes is chosen, so that variables reducing heterogeneity most have
greater chances of being selected than the background noise variables (Biau, 2012). Binary
splits lead to trees, and then aggregated results within the terminal nodes are used for
prediction. The random forests by create a more stable tree structure and reduce variance
by combining a large number of de-correlated regression trees Breiman (2001).







2, where ȳl and ȳr are the average values
within left and right child nodes) (Hastie et al., 2009). But robust random forests for
regression have been studied Roy and Larocque (2012). Several modifications based on
standard RF can be made to gain robustness including LAD-based splitting rule (Breiman
et al., 1984), aggregating the predictions over the trees using the median values. Empirical
studies have demonstrated that these modifications offer more protection against outliers
than the standard RF in most cases.
The robust RF-based CATE estimator we propose follows a similar structure. However,
robust RF splits the samples based on weighted LAD (or WLAD) rule, a variant of the














are leaf node medians to increase robustness and w∗i is the weight of each
observation. For prediction, we used the mean of the medians that consist of the WLAD
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splitting rule as the final prediction as in Meinshausen and Ridgeway (2006) instead of the
median of mean in Roy and Larocque (2012).
Algorithm 2: Robust RF-based CATE estimating algorithm
1 Input: Data {(Yi, Ti,Xi)}ni=1, number of trees T , fraction of features used in
splitting pfraction, minimum node size k, boostrap sample size N .
2 Estimate nuisance quantities p(x), µ(x), µ(1)(x), µ(−1)(x) using (robust) GBM;
3 Calculate w∗i and y
∗
i according to Table 3.2 and Formulation (3.3);
4 for t in 1,...,T do
5 a. Randomly select N observations with replacement from the dataset as the
bootstrap sample and randomly select a subset of variables with size
pfraction × p, where pfraction ∈ (0, 1);
6 b. Fit a regression tree by repeating following steps until we reach the
minimum node size k:
7 b.1 Find the variable and the cutoff value that best split the data into two
child nodes based on (3.4);
8 b.2 Split the current node into two child nodes;
9 c. Calculate the median of the transformed outcomes in each terminal node as
CATE estimator;
10 end
11 Output: Splitting criterion and CATE estimators of terminal nodes.
The important tuning parameters T , pfraction, k, and N can be selected by cross vali-
dation.
Robust Gradient Boosting Machine Learner
Gradient boosting machine (GBM) is a supervised learning technique that produces a pre-
diction model f̂(x) in the form of sequential weak-learners, typically regression trees, so
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that it performs better in high-dimensional settings (Friedman et al., 2000; Friedman, 2001,
2002). GBM builds the model in a stage-wise fashion by allowing optimization of a dif-
ferentiable loss function Ψ(y, f). The principle idea behind this algorithm is to construct
weak-learners that are maximally correlated with the negative gradient of the loss function,
associated with the whole ensemble.
Friedman’s GBM algorithm initializes f̂(x) to be a constant. Then, in each iteration, it







A regression model g(x) is fitted to predict z from the covariates x. Finally, it updates the
estimate of f(x) as f̂(x) ← f̂(x) + λg(x), where λ is the step size. Friedman (2001) also
proposed LAD-TreeBoost algorithm, a variation of GBM, which is highly robust against
outliers. Ridgeway (2007) later extended the LAD-TreeBoost algorithm to a weighted
version.
In the proposed robust GBM for CATE estimation, we further extended Ridgeway’s
algorithm by combining it with the unified CATE estimation formulation as follows:
44
Algorithm 3: Robust GBM-based CATE estimating algorithm
1 Input: Data {(Yi, Ti,Xi)}ni=1, number of trees T , fraction of observations used in
splitting psample, interaction depth c, and step size λ.
2 Estimate nuisance quantities p(x), µ(x), µ(1)(x), µ(−1)(x) using (robust) GBM;
3 Calculate w∗i and y
∗
i according to Table 3.2 and Formulation (3.3);
4 Initialize f̂(x) to be a constant, f̂(x) = medianw∗(y
∗);
5 for t in 1,...,T do
6 a. Compute the negative gradient as the working response




7 b. Randomly select psample × n observations without replacement from the
dataset, where psample ∈ (0, 1);
8 c. Fit a regression tree to predict zi using covariates xi with interaction depth c
and the number of leaf nodes K;





i , f̂(xi) + ρ, w
∗
i ), where Ψ(y, x, w) = w|y − x| and k
indicates the index of the terminal node Sk into which an observation with
feature x would fall;
10 e. Update f̂(x) as f̂(x)← f̂(x) + λρk(x), where λ is step size.
11 end
12 Output: Splitting criterion and CATE estimates in terminal nodes.
For robust estimation, the terminal node estimate is the weighted median medianw∗(z),






= 12 . The important tuning parameters
T , λ, c, and K can be selected by cross validation.
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Robust Artificial Neural Network Learner
Artificial neural network (ANN) is a biologically inspired computer program designed to
simulate the way in which the human brain processes information (Goodfellow et al., 2016).
A no-hidden-layer ANN with identity activation function is similar to linear regression in
its model structure. But ANN with multiple hidden layers offer great flexibility for use in
real applications. A feed-forward neural network with two hidden layers can be represented
as g(x) := f3(W 3f2(W 2f1(W 1x))), where W l = (wljk) are the weights between layer l − 1
and l, where wljk is the weight between the k-th node in layer l − 1 and the j-th node in
layer l, and f l is the activation function at layer l. Multi-layer networks use a variety of
learning techniques to learn the weight factors, the most popular one is backpropagation
(Rumelhart et al., 1986). In training, the loss of the model is defined based on the difference
between the outcome y and the predicted output ŷ. The most popular loss function is Root





i=1(yi − ŷi)2). However, numerous studies have
shown that the presence of outliers poses a serious threat to the standard least squares
analysis (Liano, 1996). The L1-loss provides an effective remedy that can be applied to
ANN (i.e., 1n
∑n
i=1 |yi − ŷi|). The empirical study shows that L1-based estimator gives
better performance than that of the L2-based algorithm (El-Melegy et al., 2009) when
outliers exist.
As typical, for CATE estimation, the activation functions of hidden layers are rectified
linear activation functions (ReLUs) (Nair and Hinton, 2010) and the last activation function
is the identity function. ReLU is a piecewise linear function that will output the input
directly if it is positive, otherwise, it will output zero, and a model that uses it is easier
to train and often achieves better performance. In training, the loss of the model is the
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where C is the loss function or cost function, w∗ and y∗ are the transformed weight and
outcome in the unified formulation (3.3). Similarly, to increase the robustness, the loss




i |y∗i − ŷ∗i |). The
adaptive moment estimation (Adam) (Kingma and Ba, 2014), a gradient-based optimization
algorithm, that run averages of both the gradients and the second moments of the gradients
is adopted to train the ANN. An L1 regularization is used in high-dimensional settings in
the first layer to have a sparsifying effect by driving some weights to zero (Girosi et al.,
1995; Feng and Simon, 2017). The algorithm is as follows:
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Algorithm 4: Robust ANN-based CATE estimating algorithm
1 Input: Data {(Yi, Ti,Xi)}ni=1, number of iterations T , batch size B, Adam
parameters β1, β2, η, and ε, and L1 regularization parameter λ in high-dimensional
case.
2 Estimate nuisance quantities p(x), µ(x), µ(1)(x), µ(−1)(x) using (robust) GBM;
3 Calculate w∗i and y
∗
i according to Table 3.2 and Formulation (3.3);
4 Initialize an ANN with weights w, the decaying average of past gradients m to a
zero vector, and the decaying average of past squared gradients v to a zero vector;
5 for t in 1,...,T do
6 a. Sample a mini-batch of data {y∗, x, w∗} without replacement with size B;
7 b. Compute the negative gradients g(t) based on weighted MAE;
8 c. Update m and v by
m(t) = β1m
(t−1) + (1− β1)g(t), v(t) = β2v(t−1) + (1− β2)g(t)
2
;
9 d. Compute bias correction terms m̂(t) = m
(t)
1−βt1








12 Output: Weights w in the ANN.
The advantages and disadvantages of selected supervised learning algorithms are sum-
marized in Table 3.3. Generally, GBM outperforms RF when it is well-tuned. As ANN
is extremely flexible, it usually outperforms GBM and RF for image and text data. For
structured data (not images or text), the representation problem is easier to solved so neural
network could overkill.
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Table 3.3: Comparison of selected supervised learning algorithms
Algorithm Advantages Disadvantages Main Hyperparameters




Model can get large Number of trees,
number of features used
in splitting
GBM High-performing Harder to tune than RF,
sensitive to outliers,





Neural Network Can handle extremely
complex task




To make the proposed algorithms more accessible, we implemented these three algo-
rithms in R package RCATE, every one of them can be combined with MCM-EA, RL,
and AIPW to estimate CATE. The minimal required inputs are outcome, treatment as-
signment indicator, and pre-treatment covariates, which means there is no need for users
to estimate nuisance quantities. The usage of R package RCATE is briefly introduced in
Appendix B.1. 1
Methods for estimating confidence intervals (CIs) when using proposed algorithms have
not been developed. We calculated the empirical confidence interval using bootstrap. In
simulation experiments, for each simulated dataset, we drew 1,000 bootstrap samples. For
each subject in the testing set, the 2.5th and 97.5th percentiles of the 1,000 estimates were
taken as the lower and upper bound of CI. Then the coverage probability was calculated by
averaging across all subjects in the testing set and all simulation replications.
1The randomForest package (RColorBrewer and Liaw, RColorBrewer and Liaw) can be
used to perform the standard L2-based RF in R software (Team, 2013). The gbm package
(Ridgeway et al., 2013) can be used to perform the standard and robust GBM. The keras
(Allaire et al., 2019) and tensorflow (Allaire et al., 2016) packages can be used to perform
the standard and robust ANN.
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3.3 Simulation Studies
We conducted extensive simulations to evaluate the finite sample performance of the pro-
posed algorithms. Our first set of simulations, Simulation 1, compared the proposed L1-
based algorithms, L2-based algorithms, L1-based generalized additive B-spline model (ro-
bust GAM) (Li, 2021), and L1-based additive B-spline model combined with Q-learner
(robust QL). The last two methods were defined below:





w∗i (Xi, Ti)|Y ∗i −B(Xi)Tβ|+ Λn(β),










where Λ is a smoothness-sparsity penalty for group-wise variable selection and controls
smoothness of the regression line simultaneously. The second set, Simulation 2, compared
the proposed L1-based algorithms with existing machine learning algorithms for CATE
estimation implemented in R in high-dimensional settings. Simulation 3, showed the trade-
off between robustness to complex treatment effect function and the efficiency by comparing
machine learning algorithms with additive models. We summarized the adopted methods
in each setup in Table 3.4.
The design of the simulation setups followed the data structure of the real data in
Section 2.5. The binary treatment levels (i.e., T ∈ {−1, 1}) and continuous outcome were
used throughout. And we set the number of replications R is 1,000 times and the size
of the validation set is nν = 1, 000. Performance was assessed using mean squared error
(MSE), mean absolute error (MAE), and coverage probability (CP). The MSE and MAE
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where xv is the v-th observation from the validation set, τ̂
(r)(x) is the estimator of τ(x) based
on the r-th data replication. We summarized the performance over the whole validation
set by taking the averages (i.e.,MSE = 1nv
∑nv
v=1MSEv). For simplicity, we reported MSE
and MAE. The tuning parameters were summarized in Appendix B.4.
Table 3.4: Candidate Methods in Each Setup
Methods under the Unified Formulation Other Candidate Methods
MCM-EA RL AIPW Method
Robust RF (1)(2)(3) (1)(2)(3) (1)(2)(3) Robust QL (1)
Robust GBM (1)(2)(3) (1)(2)(3) (1)(2)(3) Causal BART (2)
Robust ANN (1)(2)(3) (1)(2)(3) (1)(2)(3) Causal Boosting (2)
RF (1) (1) (1) Causal Forest (2)
GBM (1) (1) (1) Causal MARS (2)
ANN (1) (1) (1) X-learner+RF (2)
Robust GAM (1)(3) (1)(3) (1)(3)
We designed following simulation setups to contrast the robustness to outcome irreg-
ularity and model complexity of the adopted methods, and to examine the performance
of the methods under various proportions of outliers, distribution of errors, sample sizes,
sample dimensions, and true treatment effect functions.
Simulation 1: Proposed algorithms are more robust to outliers in outcome.
We compared all considered approaches in Table 3.4 for Simulation 1 across a combination
of two design factors: the proportions of outliers po and the outliers generating mechanisms.
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We generated outcome as follows,
Yi = b0(Xi) +
Ti
2
τ0(Xi) + εi, εi ∼ (1− po)N(0, 1) + poP.
We varied the two factors in two scenarios: (1) po ∈ {0, 0.05, 0.1, 0.15, 0.2, 0.3, 0.5}, n =




We considered ten i.i.d. random variables, (Xi ∼ N10(0, 1)) and five of them were
included in the true treatment effect function. We assumed the treatment assignment
mechanism is a generalized linear model of covariates and the response surface is a nonlinear
model of covariates. Specifically, the treatment assignment followed a logistic model
Di|Xi ∼ Bernoulli(p(Xi)), Ti = 2Di − 1, logit(p(Xi)) = Xi1 −Xi2.
Two functions in the response surface were
b0(Xi) = 100 + 4Xi1 +Xi2 − 3Xi3,
τ0(Xi) = 6sin(2Xi1) + 3(Xi2 + 3)Xi3 + 9tanh(0.5Xi4) + 3Xi5(2I(Xi4)− 1),
where the true treatment effect function is a nonlinear model of covariates and includes
interactions of them.
The MSE and MAE of the CATE estimates obtained are described in Figure 3.2. The
figure showed that all L1-based algorithms outperform the L2-based ones. Advantage of
the robust algorithms increased with the proportion of outliers, under both MSE and MAE.
And as the true treatment effect function was complex containing interactions of covariates,
when po < 0.2, the proposed machine learning algorithms outperformed additive models in
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MSE and CP (CPs were summarized in tabular form in Appendix B.2). The performance
of robust GAMs were better than robust QL when the proportion of outliers was close to
the breakdown point of LAD regression, i.e., po = 0.5. There were only little practical
differences between the robust GBM, robust ANN and robust RF when combined with
MCM-EA and R-learning. But the robust GBM didn’t work well together with AIPW
transformation because AIPW tends to generate transformed weights with large variance
and GBM is more likely to overfit if the data is noisy (Oza and Tumer, 2008).
Figure 3.2: Simulation results of Simulation 1
Note: MSE and MAE values of different methods under different proportions of
outliers and error generating mechanisms. The robust GBMs were indicated by
red solid line, the robust RFs were indicated by blue solid line, the robust ANNs
were indicated by green solid line. The GBMs, RFs, and ANNs were indicated
by dashed red, blue, and green lines. The robust GAMs were indicated by blue
dotted line, and robust QL was indicated by brown dotted line.
53
Simulation 2: Robust GBMs have good performance in high-dimensional set-
tings.
Only the top performed methods in Simulation 1 and CATE estimating algorithms available
in software R were used in Simulation 2. In Simulation 2, we deeply examined the perfor-
mance when data is high-dimensional and outliers exist in outcome. We generated datasets
with same outlier distributions P , baseline function, and propensity score function as the
Simulation 1. And we fixed the proportion of outliers as 0.15, sample size as n = 1, 000,
and data dimension as p ∈ {100, 2000} to compare the performance of different methods
in high-dimensional case. This is a reasonable setup because many observational data are
long and wide like EHR data and insurance claim data.
The true treatment effect functions when p = 100 and p = 2000 were
τ0(Xi) =6sin(2Xi1) + 3(Xi2 + 3)Xi3 + 9tanh(0.5Xi4) + 3Xi5(2I(Xi4)− 1)+
3Xi6 + 2Xi7 +Xi8 − 2Xi9 − 4Xi10,
and
τ0(Xi) =6sin(2Xi1) + 3(Xi2 + 3)Xi3 + 9tanh(0.5Xi4) + 3Xi5(2I(Xi4)− 1)+
50∑
j=6
βjXij , βj ∼ Unif(−2, 2),
correspondingly.
Figure 3.3 (A) and (C) showed the results when p = 100, the robust GBMs and robust
ANN combined with AIPW and MCM-EA beated all other algorithms when outliers exist.
The causal MARS was the best performing existing algorithm. Robust Rs and robust ANN
combined with RL tied with causal MARS. Boosting-based algorithms generally performed
better than forests-based ones. This is because a single deep tree struggles to achieve
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low bias on large high dimensional data, so as the forest. Then we further increased the
dimension to p = 2000 for robust GBMs, robust ANN combined with AIPW and MCM-EA,
and causal MARS, Figure 3.3 (B) and (D) showed that robust GBMs perform the best when
the data dimension is much larger than the sample size.
Figure 3.3: Simulation results of Simulation 2
Note: MSE of different algorithms when data is high-dimensional and
outliers exist. Figures A and C showed the results when p = 100,
Figures B and D showed the results when p = 2000.
Simulation 3: The trade-off between flexibility and efficiency.
In Simulation 3, we more deeply examined the trade-off between flexibility and efficiency.
We conducted this setup because if the treatment effect function is additive, the flexible
machine learning algorithms may be overkill, even though, in real application, the additivity
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assumption is almost impossible to hold. We want to show that when the sample size
available for proposed algorithms is large enough, their performance would be comparable
to the performance of robust GAMs with a smaller sample size.
We used the same data dimension, outliers distribution P , the number of confounders,
the treatment assignment, and outcome generating mechanisms as in Simulation 1. And
we fixed the proportion of outliers as 0.15. The true treatment effect function was
τ0(Xi) = 6sin(2Xi1) + 3Xi2 +Xi3 + 9tanh(0.5Xi4) + 3Xi5.
And for sample size, we considered two scenarios: (1) For robust GAMs, the sample size
was fixed as n0 = 200, and for robust GBMs, robust RFs, and robust ANNs, the sample
size increased from 200 to 1000 by 200; (2) For robust GAMs, the sample size was fixed
as n0 = 1000, and for proposed robust algorithms, the sample size increased from 1000 to
7000 by 2000.
From Figure 3.4, we can see that as the sample size used by machine learning algorithms
increase, their performance became better. Therefore, without making additive assumption,
the machine learning algorithms could have as good performance when the sample size is
around seven times of the sample size used by robust GAMs.
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Figure 3.4: Simulation results of Simulation 3
Note: MSE of different methods under different sample sizes. The robust GBMs
were indicated by red solid line, the robust RFs were indicated by blue solid line,
the robust ANNs were indicated by green solid line. The robust GAMs were
indicated by blue dotted line. In the first and third columns of figures, the
sample size of robust GAMs methods was n0 = 200; in the second the fourth
columns of figures, the sample size of robust GAMs methods was n0 = 1000.
We further compared the speed of proposed algorithms and additive models under dif-
ference sample sizes and dimensions of data. The robust RF was completely implemented
in R, so that the speed is relatively slow and not included in the comparison here. We can
see that (robust) GBM ran faster than other methods. And all proposed methods ran faster
than robust GAM when the sample size or dimension is high.
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Table 3.5: Comparison of the speed (s) of RF/GBM/ANN and additive model
Dimension Algorithm n = 1000 n = 3000 n = 5000 n = 8000
p = 10
Random Forests 0.30 1.67 3.34 7.41
GBM 0.28 0.79 1.29 2.13
Robust GBM 0.29 0.99 1.63 2.58
ANN 4.72 12.87 21.43 35.89
Robust ANN 4.51 12.63 20.90 35.25
Robust GAM 1.65 18.94 38.23 86.18
p = 100
Random Forests 2.54 12.99 28.71 60.51
GBM 2.27 6.64 11.33 18.75
Robust GBM 2.29 7.13 12.13 19.02
ANN 5.24 14.29 25.05 39.13
Robust ANN 5.24 14.22 24.63 42.04
Robust GAM 33.65 243.24 N/A N/A
In summary, when data dimension is low and proportion of outliers is less than 0.2,
proposed robust algorithms outperform other adopted methods; when data dimension is
high, robust GBMs are suggested to use. In addition, robust GBMs have the fastest speed.
3.4 Data Application
We analyzed the data with the proposed algorithms. According to Section 3.3, robust
RF and GBM combined with MCM-EA and R-learning performed better than the other
methods when the sample size and proportion of outliers were relatively small. Therefore, we
used these four methods to estimate CATE. When conditioned on the average of continuous
covariates and majority of binary covariates, τ̂ gradually decreased with an increasing PDC
(Figure 3.5), implying that the BP lowering effects of the combination therapy improved
when patients becoming more adherent to the prescribed medicines. The Figure 3.5 showed
that the BP-lowering effects of the combination therapy were significantly better than that
of ACEI alone therapy when adherence level is close to 1 (meaning the patient is nearly
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perfectly adherent to the prescribed medicines), a finding that is more in line with the
clinical expectation and consistent with existing knowledge and the results in Section 2.5.
Figure 3.5: Marginal treatment effect of PDC.
Note: If the empirical 95% C.I. not covers zero, the interval segment was colored
green or red.
We further showed the joint treatment effect of PDC and BMI. Figure 3.6 showed that
the combination therapy works the best for hypertensive patients whose BMI is between 30
and 40.
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Figure 3.6: Joint treatment effect estimation of PDC and BMI.
Note: The estimates were represented by various colors. The
estimates less than zero are in blue, and the estimates whose
empirical 95% C.I. covers zero are in grey.
The p-values of the conditional independence test were summarized in Table 3.6. The
conditional independence error assumption held for four adopted methods at the significant
level of 0.05.
Table 3.6: Conditional independence test results (p-value)
Method IRD-test IEP-test ICQP-test ITP-test IRP-test
Robust RF + MCM-EA 0.46 0.29 1.00 1.00 0.26
Robust RF + RL 0.33 0.29 0.57 1.00 0.28
Robust GBM + MCM-EA 0.65 0.81 0.24 0.43 0.66
Robust GBM + RL 0.21 0.71 1.00 0.43 0.34
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3.5 Discussion
In the previous chapter, we described a general estimating equation for heterogeneous treat-
ment effect estimation. The formulation is highly flexible and can accommodate high di-
mensional observational data with various forms of irregularity. Nevertheless, the method
requires correct specification of the treatment effect function. Although we attempted to
alleviate the constraint by using a more flexible additive structure, there is no guarantee
that the additive structure is, in fact, correct. The approach, although theoretically appeal-
ing, cannot be readily applied in many analytical situations, especially when the treatment
effect functions contained interactions among the independent variables.
In this chapter, we extend the robust estimation methods for heterogeneous treatment
effects. We further reduce the methods’ reliance on correct model specification by using
algorithm-based machine learning techniques, including random forest, gradient boost ma-
chine, and artificial neural network, to determine the correct model formulation. In a sense,
we let the model specification be data-driven. In doing so, we hope to retain the good theo-
retical properties described in the previous chapter while making the estimation procedure
more robust against model misspecification. The essence of this general approach is to use
machine learning techniques to optimize the common objective function. Simulation results
confirm that the new procedures’ good performance. In addition to the added robustness
against model misspecification, the added flexibility of the methods further enhances the
general scalability of the robust heterogeneous treatment effect estimators.
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Chapter 4
Reinforcement Learning for Dynamic Treatment Recommendation
Recommendation of a particular regimen to optimize the treatment outcome in an individual
patient is perhaps the most essential task of precision medicine. In real-world therapeutics,
the task has to be accomplished in a dynamic setting: drugs are initiated or stopped based
on a patient’s response, often in an environment depicted by a Markov process. Such a
setting would make reinforcement learning a suitable technique for treatment selection.
However, depending on the management practice of specific diseases and the data sources
used to train the policy, reinforcement learning techniques must be modified to achieve this
goal.
4.1 Treatment recommendation: An application in hypertension
In this chapter, we describe a reinforcement learning (RL) algorithm for recommending
antihypertensive therapies using a static data source. For narrative convenience, we present
the methodological development in the context of hypertension treatment, a setting that
presents some unique challenges. We first describe the context of this research.
Hypertension is a major contributor to mortality and morbidity in the United States.
Nearly half a million of people died in 2018 because of hypertension-related sequelae.
Widespread monitoring and control of blood pressure is not optimal; many individuals
with elevated blood pressure do not know that they are hypertensive. By some estimates,
only about 1 in 4 adults (24%) with hypertension have their blood pressure controlled at a
level below 130/80 mmHg (Centers for Disease Control and Prevention, 2019). The latest
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evidence suggests that reducing systolic blood pressure (SBP) to 120 mmHg would produce
the greatest health benefit (SPRINT Research Group, 2015).
Pharmacological therapy is the mainstay approach for lowering blood pressure, while
lifestyle modifications can aid in the management of blood pressure. However, the current
pharmacological treatments have been largely empirical. With a large number of antihy-
pertensive agents available, physicians rely on published evidence and their own experience
to determine how to treat individual patients, often by trial and error. Adding to the
difficulty, there are many antihypertensive drugs, relying on different mechanisms to lower
blood pressure. In addition, combination therapies are commonly used to gain better treat-
ment effects. Moreover, the optimal treatment may change over time, according to the
patient’s dynamic responses, and the treatment effect is also influenced by the variations in
the patient’s physiological and pathological states.
Therefore, an evidence-based personalized treatment recommendation system is needed
to assist doctors in making treatment decisions. A well-designed system could protect
patients from adverse events and save time and money spent trying different drugs or putting
patients on more drugs than necessary. An excellent source of data for the development of
such a system is electronic health records (EHRs). Large clinical studies also generate useful
data. In this work, we built an evidence-based recommendation system for antihypertensive
agents using data from the Systolic Blood Pressure Intervention Trial (SPRINT) (SPRINT
Research Group, 2015). SPRINT was a large clinical trial aimed at lowering SBP in patients
with essential hypertension. We used RL as a general approach but modified the algorithms
to address the unique challenges in this study.
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4.2 Data source
The research question and data source we used are from the SPRINT study that was a
large clinical trial designed to reduce cardiovascular morbidity and mortality by setting a
lower SBP target of less than or equal to 120 mmHg. Although it was a randomized trial,
its purpose was not to test the efficacy of specific drugs. Instead, the SPRINT study left
the therapeutic decisions to the physicians. For this reason, it provides a platform for the
development of a drug recommendation system.
The SPRINT study recruited and followed 9,361 patients who were at least 50 years
old, with an SBP of 130-180 mmHg and increased cardiovascular risk, but without dia-
betes. Participants were randomly assigned to the intensive treatment group (SBP target
of 120 mmHg or lower, n=4,678), and the standard treatment group (SBP target of 120-140
mmHg, n=4,683). Participants were seen monthly for the first 3 months and every 3 months
thereafter for up to 5 years. Medications for participants were adjusted based on the most
recent visits to reach the target SBP. Demographic data and clinical/subclinical chronic
vascular and kidney diseases were recorded at baseline. Laboratory data, cardiovascular
and kidney diseases, prescriptions, and SBP measurements were updated in each visit. The
most common antihypertensive regimens used in the SPRINT study were thiazide-type di-
uretics, angiotensin-converting-enzyme inhibitors (ACEIs), angiotensin II receptor blockers
(ARBs), calcium channel blockers (CCBs), alpha/beta-blockers, and combinations of these
drugs (see Figure 4.1).
We considered the optimization of treatments within the framework of a dynamic treat-
ment regimen (DTR). A DTR is a sequence of regimens tailored by the dynamic states
of patients. In DTR recommendation, not only the immediate but also the long-term
treatment effects are considered in order to account for the delayed effects of the current
treatment as well as the effects of the future treatments. Therefore, an optimal DTR is de-
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Figure 4.1: The frequency of use of each of the antihypertensive drug classes and their
combinations in the SPRINT data.
termined by optimizing the long-term evaluation metric related to the outcome of interest.
Developing such a system to find the optimal DTR is rarely a straightforward process. We
approach the problem by taking into account the unique features of the SPRINT data.
We modeled the DTR as a Markov decision process (MDP). Within such a system, a
policy can be trained by an RL algorithm to return an optimal regime that maximizes the
future reward in a given dynamic state. RL has been applied to many chronic diseases,
including heart disease, cancer, diabetes, anemia, HIV, and mental diseases (Gottesman
et al., 2019; Yu et al., 2019; Liu et al., 2020). However, RL has not been applied to long-
term blood pressure control because of the unique challenges in the application.
4.3 DRT Recommendation using Reinforcement Learning
4.3.1 Preliminaries on Reinforcement Learning
In this research, the DTR is modeled as an MDP with a deterministic policy. The MDP is
formed by (S,A, p, r, γ), where S and A denote the state space and action space, respec-
tively. At a given discrete time step t, an RL agent takes action a ∈ {0, 1}K from A in
state s ∈ S, and receives a new state s′ ∈ S and a reward r(s, a, s′) based on the transition
dynamics p(s′, r|s, a). K is the number of action dimensions that will be introduced in the
following subsection. The agent makes decisions by its policy π : S → A. For a given policy
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π, the state-action value function (or Q-function) is defined as the expected reward of an
agent, i.e., Qπ(s, a) = Eπ[Rt|s, a], where Rt =
∑∞
i=t γ
(i−t)r(si, ai, si+1) is the cumulative
discounted future reward (or return) from time step t, and γ is the discount factor that
determines the effective horizon by weighting future rewards. The goal of RL is to find
an optimal policy that attains the maximum Q-value. Mathematically, the optimal value
function is defined as Q∗(s, a) = maxπ Q
π(s, a) for any π, s, and a. For γ ∈ [0, 1), the
optimal Q-function is the unique solution to the Bellman optimality equation (Bellman,




p(s′, r|s, a)[r(s, a, s′) + γmax
a′
Q∗(s′, a′)].
In deep RL, a neural network Qθ is used to approximate the Q-function. In the Deep
Q-Network (DQN) (Mnih et al., 2015), the Q-function was updated by minimizing the







′, a′)−Qθ(s, a)), (4.1)
where lδ is the Huber loss (Huber, 1992):
lδ(x) =

0.5x2 if x ≤ δ,
δ(|x| − 0.5δ) otherwise.
We used Huber loss to avoid large TD error gradients. The loss was minimized over mini-
batchesMi, i = 1, ..., I of sampled transitions (s, a, s′, r), where I is the number of iterations.
To maintain a relatively fixed target, the double DQN (DDQN) was proposed by Van Hasselt
et al. (2015). The two DQNs are a primary network Qθ and a target network Qθ′ that are







′, a′)−Qθ(s, a)),where a′ = argmaxa′Qθ(s′, a′). (4.2)
With the above loss function, a target network Qθ′ can be soft-updated (Lillicrap et al.,
2015) by θ′ = ηθ+(1−η)θ′, where η is a parameter with a value close to zero. An extension
of the DDQN is the dueling double DQN (D3Q) (Wang et al., 2016). The D3Q explicitly
separates the representation of state value and state-dependent action advantages into two
separate streams while sharing a common learning module. The two streams are then
combined into a special aggregating layer to produce an estimation of the Q-function,









The dueling network architecture has been shown to lead to better policy evaluation in
the presence of many similar-valued actions, and thus, it achieves faster generalization over
large action spaces (Wang et al., 2016).
As introduced above, an RL agent does not learn by mimicking the actions in the
data set. Instead, an RL agent learns based on interactions with the environment, which
distinguishes RL from supervised learning (SL), where the correct (or best) actions need to
be provided. A clear limitation of SL is that the behavior cloning agent can only be as good
as the human it is imitating. However, RL can outperform the human. Also, in RL, the
environment does not need to be modeled. Model-free RL algorithms can directly develop
a control policy based on interactions with the environment. RL also considers the delayed
effect of current action and the effect of future actions, which uniquely suits the DTR
recommendation task because treatments usually have delayed effects and the regimens do
not change dramatically over time (see Figure 4.2). Moreover, RL can return a personalized
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optimal treatment based on a patient’s dynamic state, rather than on the average treatment
effect from a randomized clinical trial. These features make RL an attractive solution to
construct a DTR recommendation system for chronic diseases.
Figure 4.2: The SBP, dystolic blood pressure (DBP) measurements, and prescriptions of
two patients in the standard group (top) and the intensive group (bottom) in the SPRINT
study.
4.3.2 Challenges and related works
There is a growing literature on healthcare applications of RL. However, there are several
unique challenges that made RL ill-fitted in DTR recommendation. First, when EHR or
large study data are the main source of training, the data source is observational. The
regimens are prescribed by experienced and knowledgeable physicians. We would not want
to apply policies that are not well learned on real patients, for safety and ethical reasons.
In other words, continuous data collection is not always possible. And many standard
RL algorithms have been shown to fall short in offline settings (i.e., situations of learning
using static data). For some diseases, this is not a big problem because some accurate
simulators are available to simulate the complex interaction between treatments and the
outcome. For example, the chemotherapy - tumor growth model of cancer (De Pillis and
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Radunskaya, 2003) and the glucose - insulin dynamic system of diabetes (Daskalaki et al.,
2010). However, for hypertension, many drugs can be used for blood pressure management;
but the mechanisms of drug action can be quite different. So, there are no generally accepted
antihypertensive drugs - SBP model for use. Second, the number of antihypertensive drugs
is large, and they can be taken alone or in combination to achieve the desired effect. As a
result, the action space will increase exponentially with the number of drug classes. It is
difficult to efficiently explore the large action space with a fixed data (Lillicrap et al., 2015).
Third, safety of the recommended regimen by RL policy cannot be guaranteed because the
method learns by optimizing the Q-value at particular state. A less desirable situation is to
have a regimen containing too many working drugs, a phenomenon known as polypharmacy.
In this section, we first review the related methods, and then we propose remedies to
address these difficulties simultaneously.
Offline reinforcement learning.
In offline RL, the data set is static and has no additional accumulation because no
further online interactions with the environment occur. Decision-making in healthcare is
usually made in the offline setting (Levine et al., 2020). In offline learning, when selected
actions a′ = argmaxa′Qθ(s
′, a′) in (4.2) are barely seen in the static data, the Q-function
Qθ′(s
′, a′) could lead to an extrapolation error (Fujimoto et al., 2019) or a distribution shift
(Levine et al., 2020). The standard RL algorithms may diverge or otherwise yield poor
performance in the offline setting (Fujimoto et al., 2019; Agarwal et al., 2019). Modern
offline RL algorithms that have been proposed recently have been shown to work in the
offline setting. They can be categorized into two categories: policy constraint algorithms
(Fujimoto et al., 2019; Laroche et al., 2019; Kumar et al., 2019; Jaques et al., 2019) and
some less conservative algorithms (Yu et al., 2020; Kidambi et al., 2020; Kumar et al., 2020;
Agarwal et al., 2020). Policy constraint methods require behavior policy estimation and set
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a constraint in various ways to avoid an extrapolation error. The less conservative methods
tackle the extrapolation error by adding a regularization or a penalty of uncertainty to the
reward or value function. Policy constraint methods often work well when the behavior
policy distribution is easy to model and the static data is from human experts. Batch-
constrained deep Q-learning (BCQ) (Fujimoto et al., 2019), a policy constraint algorithm,
is one of the best offline RL algorithms that operates in a discrete action space. Basically,
BCQ uses a generative model Gω(a|s) to compute the probabilities of each action, given a
state, and utilizes some threshold to eliminate actions that are unlikely to be contained in
the fixed data. The action selection step in (4.2) becomes:







As shown in the experimental results (Fujimoto et al., 2019), offline RL can outperform
SL. Unlike SL, which mimics the choice in static data, offline RL tries to find good choices
in the data, and then recombines and applies the good choices to other subjects.
Large discrete combinatorial action space. Even though D3Q can handle a rela-
tively large discrete action space, it is not efficient enough when the action space is com-
binatorial. Metz et al. (2017) developed an approach to sequentially predict the action
value. This required manually ordering the action dimensions, which is hard in clinical
decision-making. Independent DQN (IDQ) (Tampuu et al., 2017) combines DQN with in-
dependent Q-learning. In IDQ, each agent independently and simultaneously learns its own
action value function. The Branching Dueling Q-Network (BDQ) (Tavakoli et al., 2017), a
variant of D3Q, uses a common learning module for state and all action dimensions. Each
semi-independent action branch returns the advantages of the sub-actions for that action
dimension (see Figure 4.3). Formally, for an action dimension d ∈ 1, ...,K with |Ad| discrete
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sub-actions, the branch d’s Q-value at state s ∈ S with sub-action ad ∈ Ad is expressed in
terms of the common state value V (s) and the corresponding sub-action advantage Ad(s, ad)
by:
Qdθ(s, ad) = Vθ(s) +






BDQ has been shown to scale robustly to environments with high-dimensional action spaces
to solve the benchmark domains (Tavakoli et al., 2017).
Figure 4.3: A visualization of the architecture of BDQ.
In the example of hypertension, the number of action dimensions is the number of
different antihypertension drug classes K, and the sub-actions are taking the drug (1) or
not taking the drug (0). For D3Q, the size of the output layer is 2K . With the branching
structure, the number of neurons in the output layer decreases from 2K to 2K .
Medication safety. Recently, algorithms that combine RL and SL to avoid the risks
of actions and to improve learning efficiency have been proposed. Common examples are
supervised actor-critic (Rosenstein et al., 2004) and RL from demonstrations (Vecerik et al.,
2017; Hester et al., 2018). The supervised actor-critic uses expert behaviors to pre-train a
“guardian” and sends low-risk actions to train the agent. However, SL and RL agents cannot
learn from each other in the training process. The RL from demonstrations does pre-training
solely using demonstration data (or expert behaviors) and by combining the TD error and
SL error to get a reasonable policy as the start point. Then, both use demonstration data
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and self-generated data for updating. While effective, RL from demonstrations is inadequate
for offline learning, since it requires further data collection or access to an oracle (Fujimoto
et al., 2019). These requirements are not in line with clinical reality. In addition, some works
combine actor-critic and SL to optimize the parameter θ jointly in critical care applications
(Wang et al., 2018; Yu et al., 2020). The objective function is:
L(θ) = (1− ε)LRL(θ) + εLSL(θ), (4.4)
where LRL(θ) is the objective function of RL task, which tries to maximize the expected
return, LSL(θ) is the objective function of SL task, which tries to minimize the difference
between selected the action and the doctor’s prescription, and ε is a weight parameter to
trade off the RL and SL tasks.
4.4 Proposed Modification
In this section, we describe a new algorithm, called supervised batch-constrained branching
dueling double deep Q-network (SBC-BDQ), for simultaneously handling all of the chal-
lenges in DTR recommendation for hypertension patients. The components in SBC-BDQ
are generalizable to DTR recommendation for other chronic diseases.
First, for blood pressure control, no generally-accepted metrics are available to quantify
the long-term effects of a recommended regimen. In critical care, mortality is generally used
for evaluation. However, for hypertension and many other chronic diseases, a more appro-
priate evaluating metric is needed. We propose a weighted moving average-based metric
that assigns larger weights to more recent blood pressure observations for evaluating long-
term blood pressure maintenance. This idea can be easily generalized to other applications
whose goal is to maintain biochemical indexes (e.g., blood glucose for diabetes). Second,
SBC-BDQ applies modern offline RL to DTR recommendation. This is crucial because
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continuous data accumulation is not available in most healthcare applications. Also, an ac-
curate simulator is not available for many chronic diseases. To reduce extrapolation error,
we used batch-constraint in offline learning because policy constraint algorithms generally
perform well when static data is collected by an expert, and in healthcare applications, an
aggressive constraint on action is needed. In the proposed algorithm, we extended the idea
of batch-constraint to a combinatorial action space case. Third, to avoid learning ineffi-
ciently, we adopted the branching architecture proposed by Tavakoli et al. (2017) for DTR
recommendation. If the dose level is available in the data source, the proposed algorithm
for DTR recommendation can be easily extended to do a DTR dosage search. In addition
to Q-value branches, we added supervised branches in the architecture to guarantee the
medication safety. With the modified architecture, we combined deep Q-learning and SL in
network updating. The results showed that supervision from experts can improve long-term
blood pressure maintenance.
We present the architecture of SBC-BDQ in Figure 4.4. Each component of SBC-BDQ
is introduced in detail in following paragraphs.
Figure 4.4: A visualization of the proposed SBC-BDQ agent. Each branch is made
up of the Q-value dimension and the supervised dimension.
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Common State-Value Estimator
SBC-BDQ uses a common learning module for state and all action dimensions (see Fig-
ure 4.4). The Q-value of branch d is represented by
Qdθ(s, ad) = Vθ(s) +






Finally, with the well-learned policy, in each action branch d, the sub-action a∗d that max-
imizes the Qdθ(s, ad) in state s will be recommended. The final recommended action is
a∗ = (a∗1, ..., a
∗
K). The supervised dimensions in Figure 4.4 are added for combining RL and
SL, and they will be introduced later.
Batch-Constraint for Combinatorial Action Space
In BCQ (Fujimoto et al., 2019), the conditional probability of action is predicted by a
multi-class classification neural network. A threshold is utilized to eliminate actions that
are not possible for physicians to select at a state. To adapt the large combinatorial discrete
action space, we need to use multi-label classification neural network as a generative model
Gω, where multiple labels can be assigned to each instance. Different from a multi-class
classification network whose outputs sum up to one, the last activation function of a deep
multi-label classification neural network is a sigmoid instead of a softmax function; therefore,
the outputs do not add up to one. Formally, the outputs of a multi-label classification




ω ) ∈ (0, 1)K . The conditional probability of each action is




ω(s). Then, a threshold τ is used to eliminate actions:











To adaptively adjust this threshold, we scale it by the maximum probability from the
generative model over all actions. This allows only actions whose relative probability is









−adlogpdω(s)− (1− ad)log(1− pdω(s)). (4.6)














Combining Reinforcement Learning and Supervised Learning
For each action dimension, the softmax function f is applied to adjusted sub-action advan-
tages to values between zero and one, i.e.,
qdθ (s) = f





 ∈ (0, 1)|Ad|.
For prescriptions by the doctors, we transferred each drug assignment ad to a
∗
d by one-hot
encoding. For example, when the sub-action space size |Ad| = 2, we transferred (1)→ (0, 1)
and (0)→ (1, 0). Then, we minimized the difference between qθ(s) and the doctors’ decisions












−a∗djlog(qdθj(s))− (1− a∗dj)log(1− qdθj(s)).
The whole objective function was then the weighted sum of LRL(θ) and LSL(θ) as in (4.4).
We summarize the SBC-BDQ in algorithm 5.
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Algorithm 5: SBC-BDQ
Input: Batch B, number of iterations I, target network soft update rate η,
mini-batch size M , weight parameter ε, number of classes of drugs K,
threshold τ .
1 Initialize primary Q-network Qθ, target Q-network Qθ′ with θ
′ ← θ, and generative
model Gω;
2 for i = 1 to I do
3 Sample mini-batch M contains M of N transitions (s, a, r, s′) from B;
4 aGω ← action given by Gω, where
aGω =
{
[a1Gω , ..., a
K
Gω
] : adGω = I(p
d
ω(s) > 0.5), d = 1, ...,K
}
;
5 a′ = [a′1, ..., a
′
K ], where a
′










6 Perform an Adam1step on (1− ε)LRL(θ) + εLSL(θ) with respect to θ ;
// update primary Q-network
7 Perform an Adam step on (4.6) with respect to ω ; // update generative
model
8 θ′ ← ηθ + (1− η)θ′; // update target Q-network
9 end
We used TensorFlow (Abadi et al., 2015) to implement SBC-BDQ.
4.5 Data analysis
4.5.1 Dataset and Cohort
Based on the result of the SPRINT study showing that keeping SBP below 120 mmHg
is better than 120-140 mmHg, our target SBP was set to below 120 mmHg. Therefore,
we only used transitions {s, a, r, s′} from the intensive group for training. In the intensive
1Adaptive Moment Estimation (Adam)(Kingma and Ba, 2014) is an optimizer.
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group, since more than half of the patients were on three or more classes of drugs and
had a well-maintained SBP, it was difficult to further lower SBP without adding too many
drugs. However, we could determine if the learned policy could help to recommend a
better regimen for patients who were not doing well in the SPRINT study. As shown in
Figure 4.2, even if a patient was on the same set of drugs, the SBP could change dramatically.
Therefore, we identified a cohort of transitions whose SBP increased after drug change (i.e.
SBPt+1 > SBPt and at+1 6= at) as a validation and testing set (see Figure 4.5). Finally,
we obtained 53,753 transitions from 4,436 patients as a training set, and splitted 7,470
transitions from 4,705 patients 50:50 into the validation and testing sets.
Figure 4.5: The data processing and architecture of SBC-BDQ.
4.5.2 Settings of Reinforcement Learning
For each patient, we extracted relevant parameters that included baseline and time-series
variables. The baseline patient characteristics included gender, age, race, body mass index
(BMI), SBP, smoking status, aspirin usage, statin usage, chronic kidney disease (CKD),
and cardiovascular disease (CVD) conditions. The time-series variables included lab values,
prescriptions, heart rate, adverse events, and the outcome of interest (i.e., SBP). The adverse
events included myocardial infarction, acute coronary syndrome not resulting in myocardial
infarction, stroke, acute decompensated heart failure, dialysis, and kidney transfer. At time
step t, the features mentioned above corresponded to the state st in the MDP. We imputed
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the missing lab values with multiple imputation, carried forward the dialysis and kidney
transfer condition, and removed transitions with a missing value in other variables. The
action was the following regimen prescribed, depending on state st, that contains the 5 most
commonly used drug classes and their combinations, i.e., at ∈ {0, 1}5. Note that transitions
whose current and following prescriptions contain other drug classes are not used in this
experiment. The reward at time t+ 1 is based on following SBPt+1,
rt+1 =

1 for SBPt+1 < 120
−1 for SBPt+1 > 140
0 for otherwise.
The relationship between hospital visits and the settings of RL is shown in Figure 4.6. For
simplicity, except for the outcome of interest (SBP), other variables included in state are
not shown in the figure.
Figure 4.6: Demonstration of the relationship between hospital visits and state, action, and
reward setting.
4.5.3 Evaluation Metrics
Evaluation methodology in DTR recommendation is a challenge, especially for chronic dis-
eases, due to the lack of long-term evaluation metrics. Thus, we propose a new moving
average-based metric to evaluate our algorithm. We used the long-term SBP maintenance
(LSPM) indicator, defined below, to measure whether policies would be helpful to keep
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w1 + w2 + w3
(w1SBPt+1 + w2SBPt+2 + w3SBPt+3) < 120
]
,
with wt+x = 1/(number of months between SBPt and SBPt+x), and the corresponding
long-term SBP maintenance score (abbreviated as maintenance score in the rest of the
chapter) is defined as p(LBPMt = 1). This metric considers the three SBP measurements
following assignment of the current regimen. Only the SBP measured in next 3 to 9 months
are covered by this metric because the effect of antihypertensive drugs is usually immediate
and can show up in several weeks. The LBPM is calculated for every transition in the
validation set. Then we fitted a curve to model the maintenance score using the Q-value
of the prescribed regimen as shown in Figure 4.7. Based on Figure 4.7, the LBPM is
positively correlated with the expected returns for all adopted methods. With these curves,
we can calculate the corresponding maintenance score of the recommended regimen. The
adopted methods and their implementation will be introduced in next subsection.
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Figure 4.7: Curve of maintenance score vs expected return of the prescribed regimen on the
validation set. The expected returns are from well-trained policies.
Inspired by Wang et al. (2018), we used the Jaccard distance to measure the distance
between the physician’s choice and the regimen recommended by different policies. The










Bi| , where N is the number of
transitions and Ai and Bi are the regimens from the physician and the policy, respectively.
In addition, we calculated the correlation between the maintenance score and the number
of drug classes in the validation set. Figure 4.8 shows that when a drug class was added
into the regimen, the maintenance score increased by about 0.025. To further guarantee
the safety of the recommended regimen, the average number of drug classes recommended
by policies was also calculated as an evaluation metric.
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Figure 4.8: Correlation between maintenance score and number of drug classes in the vali-
dation set.
4.5.4 Methods Considered
All the methods we considered in the experiments are as follows.
Supervised Batch-constrained BDQ (SBC-BDQ): SBC-BDQ, the proposed method,
is introduced in Section 4.4. The hyper-parameters are listed in Table 4.1.
Table 4.1: Hyper-parameters used in SBC-BDQ
Hyper-parameter Value
Network optimizer Adam
Learning rate of SBC-BDQ 0.001
Learning rate decay rate of SBC-BDQ 0.999
Delay of decay 100
Soft updating rate of primary network 0.001
Learning rate of generative model 0.05
Discount factor 0.1
Batch size 64
Number of episodes 4000
Supervised learning weight 0.5
Hidden layer size 10
Supervised BDQ (S-BDQ): S-BDQ is a simplified version of SBC-BDQ in which the
batch-constraint is removed. The only difference between SBC-BDQ and S-BDQ is the a′
selection step. The selection in S-BDQ is based on following criterion:









Batch-contrained BDQ (BC-BDQ): BC-BDQ is a simplified version of SBC-BDQ
in which supervision from physicians is removed. BC-BDQ can be easily implemented by
setting weight ε = 0.
Branching Dueling Double DQN (BDQ) (Tavakoli et al., 2017): BDQ is a
branching variant of D3N. Compared to S-BDQ, it has supervised learning weight ε = 0,
and the a′ selection is based on (4.7).
Supervised Dueling Double DQN (S-D3Q): S-D3Q is a supervised RL method
that combines SL and dueling DQN. There were 32 different drug combinations composed
of 5 drug classes, so the number of neurals in the output layer was 32, and the number of
neurals in the hidden layer was also 32. Note that the action space (|A| = 32) was larger
than the state space (|S| = 26), so this method might be less efficient than S-BDQ.
Behavior Clone: The BC method was implemented as a multi-label classification
model with 5 neurals in the output layer. Compared to the methods that combine SL and
RL, the BC method has SL weight ε = 1.
4.5.5 Results
Table 4.2 shows the estimated maintenance score, estimated following SBP, Jaccard dis-
tance, and number of drug classes in the recommended regimen for all the adopted methods
in the DTR recommendation for the testing set. The testing set has an average mainte-
nance score 0.11, an average following SBP of 138.27 mmHg, and the average number of
drug classes is 2.02. The number of drug classes from the method that performed the best
is 2.25. Even though the policy-recommended regimen has slightly more drug classes, the
recommended regimen helps to notably improve the maintenance score.
Comparing the results of S-BDQ and S-D3Q, we can see that S-D3Q has a lower main-
tenance score. This is due to the lack of efficiency of S-D3Q, which is consistent with the
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experimental results in (Tavakoli et al., 2017). We then compared SBC-BDQ with the
simplified version BC-BDQ. The smaller Jaccard distance and the better performance of
SBC-BDQ indicates that knowledgeable supervision guarantees better performance of the
learned policy. Finally, our proposed method, SBC-BDQ, had better performance than
the simplified S-BDQ. As shown in Figure 4.9(A), the batch-constrained method tends to
choose a′ much closer to aGω , especially at the beginning of learning.
In conclusion, our proposed method outperforms all the adopted baselines. The reasons
are: 1) SBC-BDQ uses batch-constraint to avoid extrapolation error (compared to S-BDQ);
2) S-BDQ uses a branching structure to reduce the dimension of the action space (compared
to S-D3Q); 3) SBC-BDQ considers the prescriptions of physicians as supervision information
to learn a safe and robust policy (compared to BC-BDQ); and 4) SBC-BDQ regards the
treatment recommendation as a sequential decision process, reflecting the clinical practice
and using RL to optimize the long-term reward (compared to BC).
Table 4.2: Performance comparison on testing set for regimen recommendation. Thiazide di-
uretic is the first-line drug, ACEI, ARB, and CCB are the second-line drugs, and alpha/beta-




















SBC-BDQ 0.360 128.90 0.479 0.57 1.23 0.45 2.25
S-BDQ 0.275 132.27 0.480 0.57 1.23 0.45 2.25
BC-BDQ 0.146 136.85 0.744 0.28 1.24 0.47 1.99
BDQ 0.146 136.89 0.755 0.28 1.22 0.47 1.97
S-D3Q 0.120 137.96 0.502 0.87 1.35 0.47 2.69
Behavior Clone 0.120 137.70 0.488 0.57 1.16 0.45 2.18
Figure 4.9(C) shows how the observed maintenance score changes with the difference
between the learned policy from SBC-BDQ and the doctors’ prescriptions from the valida-
tion set. We calculated the difference as the hamming distance, i.e. |Ai −Bi|, with Ai and
Bi as the regimens from the physician and the algorithm, respectively. When the difference
is minimal, we obtained the highest maintenance score (0.58). This shows that SBC-BDQ
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could learn good policy, and that the doctors’ prescription worked well, in general, for
patients in the validation set. Figure 4.9(B) shows the effect of the weighting parameter
ε. SBC-DQN achieved the highest maintenance score and a relatively low Jaccard distance
when the value of the weighting parameter was 0.5. This verifies that SBC-BDQ can signifi-
cantly reduce the estimated maintenance score and recommend safe regimen simultaneously.
Figure 4.9(D) shows the effect of the discount factor γ. The evaluation metric (maintenance
score) is optimized when γ = 0.1.
Figure 4.9: (A) Comparison of the distance between a′ selected by SBC-BDQ and S-BDQ
and aGω from the generative model. (B) The effect of ε on the testing set. (C) Correlation of
the observed maintenance score of the validation set and the difference between the optimal
policy and the physicians’ decision. (D) The effect of the discount factor γ on the testing
set.
Additional simulation was conducted to compare the multi-class classification model
and the multi-label classification model. All transitions in the SPRINT data were used. If
we only considered the 5 most popular drug classes, there were 32 distinct regimens. When
we considered all 10 drug classes, there were a total of 308 distinct regimens. The Jaccard
scores from the multi-label classification model and the multi-class classification model were
84













Bij | , whereNj is the number of transitions in j-th fold, and
Aij and Bij are the regimens from the physician and the classification models, respectively.
Table 4.3: Simulation result from the comparison of classification models (Jaccard score)
Setup Multi-label classification Multi-class classification
All 10 drug classes 0.917 0.903
5 popular drug classes 0.924 0.920
4.5.6 Case Study
Figure 4.10 summarizes the regimens recommended by SBC-DQN and compares the fre-
quencies of the recommended and prescribed drug classes. As the current SBP, baseline
CKD condition, baseline CVD condition, race, and gender are all important for regimen
recommendation, we compared the regimens using all these factors. In general, we recom-
mend more thiazide-type diuretics, ACEI, and CCB to patients in the testing set. Based
on the overall change, for a patient without a baseline CKD condition, we recommend less
ARB. For patients with a baseline CVD condition, we recommend more ACEI and CCB,
and less ARB. For a patient whose current SBP is greater or equal to 180, we recommend
more thiazide-type diuretics, CCB, ARBs, and alpha/beta-blockers, and less ACEIs.
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Figure 4.10: Comparison of recommended regimen and prescriptions.
4.6 Discussion
In this chapter, we propose a DTR recommendation system to assist physicians in identifying
the personalized optimal DTR for hypertension treatment without resorting to trying all
the drugs/drug combinations while guaranteeing medication safety at the same time. We
performed comprehensive experiments on the SPRINT data and demonstrated that the
proposed system can improve the long-term SBP maintenance score by 24% for patients
who might be assigned inappropriate drugs, without drastically increasing the number of
drug classes used.
The system is based on the RL algorithm SBC-BDQ. RL can help to identify the optimal
action at a particular state by maximizing the expectation of the long-term reward. To solve
the challenges in applying RL to hypertension treatment, SBC-BDQ combines SL and RL
to ensure safety, uses a branching structure to improve the learning efficiency for a large
combinatorial action space, and extends the batch-constraint to avoid extrapolation error
in offline RL.
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While our results in applying RL to blood pressure control are encouraging, they come
with several limitations. First, the SPRINT study had an inclusion criterion of only pa-
tients more than 50 years of age. This limits the generalization of our findings to younger
patients, even though 37% of hypertension patients are younger than 60 years of age (Fr-
yar et al., 2017). This limitation can be alleviated by combining other data sources with
the SPRINT data. Second, a few less common drug classes were not considered in this
study for a lack of observations and the intended use of those drugs. These are considered
second-line or third-line drugs in the guidelines, and they are usually used for patients with
a specific conditions. For example, loop diuretics are more effective than thiazide diuretics
in patients with impaired kidney functions. Even with these limitations, our system repre-
sents an initial step towards the development of a computer-assisted tool for hypertension
drug recommendation. This study focuses on the personalized DTR recommendation of
hypertension patients. However, the methods we used to deal with the specific challenges
of hypertension can be extended to the treatment of other chronic diseases.
87
Appendices
Appendix A: Robust Estimation of HTE using Additive Model
A.1. Expressing the existing methods in the general formulation
In Section A.1, we specify the expressions of c(X,T), w(X,T), and g(X) for MCM-EA,
RL, IPW, and DR methods. We show they satisfy the constraints associated with the
general formulation. For most of the methods, the derivations are similar for L1 and L2
loss functions. So we show the derivation under the L2 loss.
(1) MCM-EA. The objective function of L2-MCM-EA method is
L(τ(x)) = E
[
(Yi − µ(Xi)− Ti2 τ(Xi))
2







Tip(Xi) + (1− Ti)/2
, c(Xi, Ti) =
Ti
2
, g(Xi) = µ(Xi).
Then





















which shows the c and w functions satisfy Conditions C1 and C2. Condition C3 (w > 0 and
c 6= 0) is clearly met. The same set of parameters can be used in L1 loss. The verification
is the same.
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∣∣∣∣Xi = x] .
We write
w(Xi, Ti) = 1, c(Xi, Ti) =
Ti − 2p(Xi) + 1
2
, g(Xi) = µ(Xi).
Then
p(x)w(x, 1)c(x, 1) + (1− p(x))w(x,−1)c(x,−1) = p(x)(1− p(x)) + (1− p(x))(−p(x)) = 0
c(x, 1)− c(x,−1) = (1− p(x))− (−p(x)) = 1.
Therefore, Conditions C1-C3 are met. The same specification works for L1 loss. The
verification of A-learning remains the same.



















, c(Xi, Ti) =
2p(Xi)(1− p(Xi))
Ti − 2p(Xi) + 1
, g(Xi) = 0.
Then




p(x) + (1− p(x)) 1
(1− p(x))2
(p(x)− 1) = 0
c(x, 1)− c(x,−1) = p(x)− (p(x)− 1) = 1.
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Therefore, Conditions C1-C3 are met. The same specification works for the L1 loss function.
(4) DR. The verification of doubly robust method is the same.
A.2. Basic properties of the general formulation
Property 1. Under conditions C1-C3,
τ0(x) = argminτ(x)E[w(Xi, Ti)(y − g(Xi)− c(Xi, Ti)τ(x))2|Xi = x, Ti = t].
Proof of Property 1.
L(τ(x)) =E[w(Xi, Ti)(Yi − g(Xi)− c(Xi, Ti)τ(Xi))2|Xi = x, Ti = t]
=p(x)E[w(Xi, Ti)(Yi − g(Xi)− c(Xi, Ti)τ(Xi))2|Xi = x, Ti = 1]
+ (1− p(x))E[w(Xi, Ti)(Yi − g(Xi)− c(Xi, Ti)τ(Xi))2|Xi = x, Ti = −1]
=p(x)w(x, 1)E[(Yi − g(Xi)− c(Xi, Ti)τ(Xi))2|Xi = x, Ti = 1]
+ (1− p(x))w(x,−1)E[(Yi − g(Xi)− c(Xi, Ti)τ(Xi))2|Xi = x, Ti = −1]
∂L(τ(x))
∂τ(x)
=− 2p(x)w(x, 1)c(x, 1)(E[Y (1)i |Xi = x]− g(Xi)− c(x, 1)τ(x))
− 2(1− p(x))w(x,−1)c(x,−1)(E[Y (−1)i |Xi = x]− g(x)− c(x,−1)τ(x))











i |Xi = x]
− g(x)− c(x,−1)τ(x))
Conditions C1-C3 and the conditional independence assumption lead us to
τ0(x) = argminτ(x)L(τ(x)). 
Property 2. When c(x, 1) = 1−p(x), the optimal augmentation function is mean outcome
function, i.e., g0(x) = µ(x).
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Proof of Property 2. We provide the optimal g(·) in this section, here “optimal” g(·) means
the one minimizing the variance of estimator. Let S(Yi,Xi, Ti; τ(Xi)) be the derivative of

















S0(Yi,Xi, Ti; τ(Xi)) + 2w(Xi, Ti)c(Xi, Ti)g(Xi) = 0,
where S0(Yi,Xi, Ti; τ(Xi)) = −2w(Xi, Ti)c(Xi, Ti)[Yi− c(Xi, Ti)τ(Xi)] is the score function
without augmentation. By Condition C1, E[2w(Xi, Ti)c(Xi, Ti)g(Xi)] = 0, the solution
of the augmented score equation always converges to τ0(·) in probability. Following Tian
et al. (2014); Chen et al. (2017), selecting the optimal g(·) is equivalent to minimizing the
conditional variance of
S0(Yi,Xi, Ti; τ0(Xi)) + 2w(Xi, Ti)c(Xi, Ti)g(Xi)|Xi = x,
where τ0(x) is the minimizer of E[w(Xi, Ti)(Yi − c(Xi, Ti)τ(Xi))2|Xi = x]. Noting that
E[{S0(Yi,Xi, Ti; τ0(Xi)) + 2w(Xi, Ti)c(Xi, Ti)g(Xi)}2|Xi = x]
=E[{S0(Yi,Xi, Ti; τ0(Xi)) + 2w(Xi, Ti)c(Xi, Ti)g0(Xi)}2|Xi = x]
+ E[{2w(Xi, Ti)c(Xi, Ti)(g0(Xi)− g(Xi))}2|Xi = x]
≥E[{S0(Yi,Xi, Ti; τ0(Xi)) + 2w(Xi, Ti)c(Xi, Ti)g0(Xi)}2|Xi = x],
where g0(x) = (1− p(x))E[Y (1)i − c(Xi, Ti)τ(Xi)|Xi = x, Ti = 1]
+ p(x)E[Y
(−1)
i − c(Xi, Ti)τ(Xi)|Xi = x, Ti = −1], which satisfies the equation
E[{S0(Yi,Xi, Ti; τ0(Xi)) + 2w(Xi, Ti)c(Xi, Ti)g0(Xi)}2w(Xi, Ti)c(Xi, Ti)η(Xi)|Xi = x] = 0
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for any function η(·). By interaction model (1) and Condition C2, the expression of g0(x) can
be further simplified to g0(x) = µ(x)+[1−p(x)−c(x, 1)]τ0(x). As τ0(·) is the unknown target,
when c(x, 1) = 1− p(x), the optimal augmentation function is mean outcome function, i.e.,
g0(x) = µ(x). 
Property 3. Under Conditions C1-C3,
τ0(x) = argminτ(x)E[w(Xi, Ti)|y − g(Xi)− c(Xi, Ti)τ(x))||Xi = x, Ti = t].
Proof of Property 3.
L(τ(x)) =E[w(Xi, Ti)|Yi − g(Xi)− c(Xi, Ti)τ(Xi)||Xi = x, Ti = t]
=p(x)E[w(Xi, Ti)|Yi − g(Xi)− c(Xi, Ti)τ(Xi)||Xi = x, Ti = 1]
+ (1− p(x))E[w(Xi, Ti)|Yi − g(Xi)− c(Xi, Ti)τ(Xi)||Xi = x, Ti = −1]
=p(x)w(x, 1)E[|Yi − g(Xi)− c(Xi, Ti)τ(Xi)||Xi = x, Ti = 1]




=− p(x)w(x, 1)c(x, 1)E[sgn(Yi − g(Xi)− c(Xi, Ti)τ(Xi))|Xi = x, Ti = 1]
− (1− p(x))w(x,−1)c(x,−1)E[sgn(Yi − g(Xi)− c(Xi, Ti)τ(Xi))|Xi = x, Ti = −1]
=− p(x)w(x, 1)c(x, 1)E[1− 2I(Yi − g(Xi)− c(Xi, Ti)τ(Xi))|Xi = x, Ti = 1]
− (1− p(x))w(x,−1)c(x,−1)E[1− 2I(Yi − g(Xi)− c(Xi, Ti)τ(Xi))|Xi = x, Ti = −1]
=− p(x)w(x, 1)c(x, 1)(1− 2P (Y (1)i < g(Xi) + c(Xi, Ti)τ(Xi)|Xi = x, Ti = 1))
−(1− p(x))w(x,−1)c(x,−1)(1− 2P (Y (−1)i < g(Xi) + c(Xi, Ti)τ(Xi)|Xi = x, Ti = −1))




(g(Xi) + c(Xi, Ti)τ(Xi)|Xi = x, Ti = 1))




(g(Xi) + c(Xi, Ti)τ(Xi)|Xi = x, Ti = −1))


















(g(x) + c(x,−1)τ̂(x)) = q, where q ∈ (0, 1), then
g(x) + c(x, 1)τ̂(x) = Qq(Y
(1)
i |Xi = x)
g(x) + c(x,−1)τ̂(x) = Qq(Y (−1)i |Xi = x).
By Condition C2 (c(x, 1)− c(x,−1) = 1), we have
τ̂(x) = Qq(Y
(1)
i |Xi = x)−Qq(Y
(−1)





i |Xi = x)−Qq(Y
(−1)
i |Xi = x)




+ εi|Xi = x, Ti = 1)−Qq(b0(Xi)−
τ0(Xi)
2




+Qq(εi|Xi = x, Ti = 1)− b0(x) +
τ0(x)
2
−Qq(εi|Xi = x, Ti = −1)
=τ0(x) +Qq(εi|Xi = x, Ti = 1)−Qq(εi|Xi = x, Ti = −1).
By Assumption 3, τ0(x) = argminτ(x)L(τ(x)). 
A.3. Asymptotic Properties
To prove Theorem 1, we introduce two lemma.
Lemma 1. Under the same assumptions as Theorem 1, Wn is asymptotically equivalent
to the (K + p) dimensional normal with mean 0 and variance G.






T δρ′(Ui), the conditional
expectation of w(Xi, Ti)c(Xi, Ti)ρ
′(Ui) with respect to Xi is as follows. First, we calculate








i − g(Xi)− c(Xi, 1)B(Xi)




i − g(Xi)− c(Xi,−1)B(Xi)





i − g(Xi)− c(Xi, 1)B(Xi)
Tβ∗)





From (6.1) to (6.2) is based on Condition C1. Then, based on the interaction model and























E[ρ′(b(Xi)− g(Xi)− [c(Xi, 1)− 0.5]τ0(Xi) + ε(1)i − c(Xi, 1)ba(Xi)[1 + õ(1)])
− ρ′(b(Xi)− g(Xi)− [c(Xi, 1)− 0.5]τ0(Xi) + ε(−1)i
− c(Xi,−1)ba(Xi)[1 + õ(1)])|Xi = xi]
}
, (4.4)
where õ(1) uniformly holds for all x by the distance between τ0(x) and B(x)
Tβ∗. From (6.3)
to (6.4) is based on Condition C2. Let ϕ(Xi, Ti) = b(Xi)− g(Xi)− [c(Xi, Ti)− 0.5]τ0(Xi) +
ε
(Ti)
i , the expectation condition of w(Xi, Ti)c(Xi, Ti)ρ





E[ρ′(ϕ(Xi, Ti))|Xi = xi, Ti = 1]− E[ρ′(ϕ(Xi, Ti))|Xi = xi, Ti = −1]
− E[ρ′′(ϕ(Xi, Ti)− α(1)c(Xi, 1)ba(Xi)[1 + õ(1)])c(Xi, 1)ba(Xi)[1 + õ(1)]|Xi = xi]




− E[ρ′′(ϕ(Xi, Ti)− α(1)c(Xi, 1)ba(Xi)[1 + õ(1)])c(Xi, 1)ba(Xi)[1 + õ(1)]|Xi = xi]
+ E[ρ′′(ϕ(Xi, Ti)− α(−1)c(Xi,−1)ba(Xi)[1 + õ(1)])c(Xi,−1)ba(Xi)[1 + õ(1)]|Xi = xi]
}
,
where α(1), α(−1) ∈ (0, 1) are from Taylor expansion. The first two terms in (6.5) inside the
brace are cancelled out based on the conditional independence error assumption (Assump-
tion 3). Finally, by the definition of Φ, we have the conditional expectation equals
p(xi)w(xi, 1)c(xi, 1)ba(xi)×{
− Φ′′([1− α(1)]c(Xi, 1)ba(Xi)[1 + õ(1)]|Xi, Ti = 1)c(xi, 1))




As the order of ba(x) is o(K
−(q+1)
n ), Assumption 2 (positivity assumption), and Conditions
C4 and C9, the conditional expectation is of o(1). This means the conditional expectation
of the score function with loss functions satisfy Conditions C7-C11 goes to zero.
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T δ [ψ(Xi, Ti, Ui)− E[ψ(Xi, Ti, Ui)|Xi = xi]]
∣∣∣∣∣


















|B(xi)T δ|2+γ{p(xi)E[|w(xi, 1)c(xi, 1)ρ′(Ui)|2+γ + o(1)|Xi = xi, Ti = 1]









where the last two steps are derived by Condition C11. The conditional variance of Zn



























∣∣∣∣Xi = xi]2} (4.7)
= Knδ
TGδ(1 + oP (1)) (4.8)
= O(Kn),
where G is the variance of Wn. Here the derivation from (6.7) to (6.8) uses the Condition
C8. Because the matrix G is positive definite and has a finite maximum eigenvalue for any
bounded function (Lemma 6.2 of Zhou et al. (1998)), there exists the constants d1 and d2
such that
d1 ≤ δTGδ ≤ d2.
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The last step is from the proof of Lemma 6.10 of Agarwal and Studden (1980) and equation
(6), for j = −p+ 1, ...,Kn, we have
∫ 1
0
p(x)w(x, 1)c(x, 1)c(x, t)ba(x)Bj(x)
T δ×






n ) = o(1) from the order of Kn in Theorem 1. Consequently, we
have E[Zn|X(n)]/
√
V [Zn|X(n)] = oP (1) and Lemma 1 holds. 
Lemma 2. Let ν be a continuous function on the interval [0, 1], then D(ν) = O(K−1n ).
Furthermore, D(ν)−1 = O(Kn).













From the property of B-spline function (De Boor et al., 1978), D(ν) is positive definite
matrix. Therefore, G(ν)−1 = O(Kn) is satisfied. 
Now, we are ready to prove Theorem 1. For simplicity we write an
as∼ bn, where random
sequence {an} and {bn}, if an/bn = OP (1).
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Yi − g(Xi)− c(Xi, Ti)B(Xi)Tβ∗ − c(Xi, Ti)B(Xi)T [β − β∗]
)
.
As this minimization problem doesn’t have explicit solution, for the convergence of
√





























i=1w(Xi, Ti){ρ′(Ui)−E[ρ′(Ui)|Xi, Ti]}{αnc(Xi, Ti)B(Xi)T δ},
where X(n) represents all the observed X. We have E[Rn(δ)|X(n), Tn] = 0 from the straight
calculation. Let




Ui − αnc(Xi, Ti)B(Xi)T δ
)




Then by Condition C9-10 with s = αnc(Xi, Ti)B(Xi)







Ui − αnc(Xi, Ti)B(Xi)T δ
)
− ρ(Ui)




w(Xi, Ti){Φ(αnc(Xi, Ti)B(Xi)T δ|Xi, Ti)
− Φ(0|Xi, Ti)− Φ′(0|Xi, Ti)αnc(Xi, Ti)B(Xi)T δ}
]2
=o(α2n).
Therefore, we have from Kn = O(n
1/(2q+3)), E[Rn(δ)
2] = 1nV [r1] = o(1) and Rn(δ) = oP (1).
By the definition of Φ(t|X,T ), the Taylor expansion of
Φ(αnc(Xi, Ti)B(Xi)
T δ|Xi, Ti)
around αn = 0, we have E[ρ(Ui − αnc(Xi, Ti)B(Xi)T δ)|Xi, Ti] =
Φ(αnc(Xi, Ti)B(Xi)
T δ|Xi, Ti) and
Φ(αnc(Xi, Ti)B(Xi)
T δ|Xi, Ti)




Φ′′(0|Xi, Ti){αnc(Xi, Ti)B(Xi)T δ}2 + o(α2n).

















Thus, we have Un(δ) as


























Φ′′(0|Xi, Ti)w(Xi, Ti)c(Xi, Ti)2B(Xi)TB(Xi).
The minimizer of Un(δ) is




which is the solution of ∂Qn(δ)/∂δ = 0. Hence, because δ̂ =
1
αn












The asymptotic variance of τ̂(x) is similar to that of τ̂(x) − τ∗(x) because Wn is the only




B(x)TGnV [Wn]GnB(x)(1 + o(1)),
where Gn = D(ν)+o(K
−1
n ) and ν(x) = p(x)w(x, 1)c(x, 1)
2ρ′′(y(1)−g(x)−c(x, 1)B(x)Tβ∗)+
(1−p(x))w(x,−1)c(x,−1)2ρ′′(y(−1)−g(x)−c(x,−1)B(x)Tβ∗) due to the Riemann integral,






























where Ψ(x) = limn→∞
1
Kn
B(x)TD(ν)−1GD(ν)−1B(x). This completes the proof. 
To prove Theorem 2, we introduce two lemmas as well.
Lemma 3. Let Ui = w(Xi, Ti)(Yi − g(Xi)− c(Xi, Ti)B(Xi)Tβ∗). Under the same assump-













where W ∼ N(0, G).






T δ[1 − 2I(Ui < 0)], the
conditional expectation of w(Xi, Ti)c(Xi, Ti)[1−2I(Ui < 0)] respect to Xi can be calculated
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as following.
E[w(Xi, Ti)c(Xi, Ti)[1− 2I(Ui < 0)]|Xi = xi]
=p(xi)w(xi, 1)c(xi, 1)E[1− 2I(Ui < 0)|Xi = xi, Ti = 1]
+ (1− p(xi))w(xi,−1)c(xi,−1)E[1− 2I(Ui < 0)|Xi = xi, Ti = −1]
=p(xi)w(xi, 1)c(xi, 1){1− 2E[I(Ui < 0)|Xi = xi, Ti = 1]
− 1 + 2E[I(Ui < 0)|Xi = xi, Ti = −1]}
=2p(xi)w(xi, 1)c(xi, 1)[P (Ui < 0|Xi = xi, Ti = −1)− P (Ui < 0|Xi = xi, Ti = 1)]
=2p(xi)w(xi, 1)c(xi, 1)
× [P (Y (−1)i < g(xi) + c(xi,−1)B(xi)
Tβ∗)− P (Y (1)i < g(xi) + c(xi, 1)B(xi)
Tβ∗)]
=2p(xi)w(xi, 1)c(xi, 1)
× [P (ε(−1)i < g(xi)− b(xi) + [c(xi, 1)− 0.5]τ0(xi) + [c(xi, 1)− 1]b
a(xi)(1 + o(1))|xi)
− P (ε(1)i < g(xi)− b(xi) + [c(xi, 1)− 0.5]τ0(xi) + c(xi, 1)b
a(xi)(1 + o(1))|xi)]
=− 2p(xi)w(xi, 1)c(xi, 1)ba(xi)fεi(g(xi)− b(xi) + [c(xi, 1)− 0.5]τ0(xi)|xi)(1 + o(1))
=o(1).
The derivation from the first equation to the second equation is by Condition C1, that from
the third equation to the fourth equation is by Model (1), that to the fifth equation is by
proposed Condition C2, the last two steps are by Taylor expansion and the order of ba(xi).
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T δ [ψ(Xi, Ti, Ui)− E[ψ(Xi, Ti, Ui)|Xi = xi]]
∣∣∣∣∣


















× |B(xi)T δ|2+γ{p(xi)E[|w(xi, 1)c(xi, 1)[1− 2I(Ui < 0)]|2+γ + o(1)|Xi = xi, Ti = 1]









where the last two steps are derived by Condition C12. The conditional variance of Zn


































2 + (1− p(xi))w(xi,−1)2c(xi,−1)2
− E
[















(1 + oP (1))
= Knδ
TGδ(1 + oP (1))
= O(Kn).
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× fεi(g(u)− b(u) + [c(u, 1)− 0.5]τ0(u)|u)dQ(u)(1 + o(1)).











n ) = o(1). Consequently, we have E[Zn|Xn]/
√
V [Zn|Xn] = oP (1)
and Lemma 3 holds. 
Lemma 4. Let win =
√
Kn
n w(xi, ti)c(xi, ti)B(xi)
T δ(i = 1, ..., n) for δ ∈ RKn+q. Then,






[I(Ui ≤ s)− I(Ui ≤ 0)]ds
as∼ KnδTDδ.



























− I (Yi ≤ g(Xi) + c(Xi, Ti)τ∗(Xi))






Yi ≤ g(Xi) + c(Xi, Ti)τ∗(Xi) +
s
w(Xi, Ti)
∣∣∣∣Xi = xi, Ti = ti)
− P
(
Yi ≤ g(Xi) + c(Xi, Ti)τ∗(Xi)




















Yi ≤ g(Xi) + c(Xi, Ti)τ∗(Xi)










g(Xi) + c(Xi, Ti)τ
∗(Xi)







g(Xi) + c(Xi, Ti)τ
∗(Xi)












g(Xi) + c(Xi, Ti)τ
∗(Xi)




g(Xi) + c(Xi, Ti)τ
∗(Xi)
∣∣∣∣Xi = xi, Ti = −1)}









2f1(g(xi) + c(xi, 1)τ0(xi)|xi)
+ (1− p(xi))w(xi,−1)c(xi,−1)2f−1(g(xi) + c(xi,−1)τ0(xi)|xi)]B(xi)B(xi)T
}
× δ(1 + oP (1))
= Knδ
TDδ(1 + oP (1)).
For i = 1, ..., n, we have
∫ win
0













[I(ui ≤ s)− I(ui ≤ 0)]ds






maxi=1,...,n {w(xi, ti)c(xi, ti)}E[Rn|Xn].
Since E[Rn|Xn] = O(Kn), we obtain
√
V [Rn|Xn]/E[Rn|Xn] = oP (1) and hence, Lemma 4
holds.
Now we are ready to prove Theorem 2.
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= U1n(δ) + U2n(δ),
where Ui = w(Xi, Ti)
(
Yi − g(Xi)− c(Xi, Ti)B(Xi)Tβ∗
)
. Then the minimizer δ̂n of Un(δ)






Following the Knight’s identity, we can write Un(δ) as



















n w(xi, ti)c(xi, ti)B(xi)







where W ∼ N(0, G). Furthermore, Lemma 4 yield
U2n(δ)
as∼ KnδTDδ.
Therefore, for both methods we obtain
Un(δ)





Because U0n(δ) is convex with respect to δ and has unique minimizer, the minimizer of

















{τ̂(x)− τ∗(x)} D→ N(0,Ψ(x)),
where Ψ(x) = limn→∞
1
4Kn
B(x)TD−1GD−1B(x) by the definition of W .






















= O(1). This completes the proof. 
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A.4. Simulation Results of Settings 1-3
Table A.1: Simulation Results for Setting 1.
ξo Measurement Bias.sq Var MSE MAE Recall Specificity Q(η̂)
0
MCMEA 0.34 0.08 0.42 0.48 1.00 0.49 1.18
L1-MCMEA 0.27 0.23 0.50 0.52 1.00 0.88 1.18
RL 0.18 0.24 0.42 0.47 1.00 0.60 1.20
L1-RL 0.14 0.32 0.46 0.50 1.00 0.93 1.19
AL 0.35 0.19 0.54 0.47 1.00 0.53 1.18
L1-AL 0.28 0.37 0.64 0.52 1.00 0.86 1.18
QL 0.35 0.16 0.51 0.43 1.00 0.30 1.17
L1-QL 0.16 0.28 0.44 0.46 1.00 0.41 1.19
0.05
MCMEA 0.92 0.59 1.51 0.95 0.90 0.50 1.04
L1-MCMEA 0.27 0.33 0.61 0.53 1.00 0.86 1.17
RL 0.55 0.79 1.34 0.88 0.94 0.49 1.07
L1-RL 0.15 0.41 0.55 0.55 1.00 0.91 1.18
AL 0.91 0.69 1.60 0.97 0.88 0.54 1.03
L1-AL 0.32 0.47 0.79 0.55 1.00 0.85 1.17
QL 0.76 0.54 1.30 0.88 0.96 0.46 1.07
L1-QL 0.17 0.31 0.48 0.48 1.00 0.43 1.18
0.1
MCMEA 1.41 0.75 2.16 1.17 0.72 0.62 0.91
L1-MCMEA 0.28 0.42 0.70 0.56 1.00 0.85 1.16
RL 1.08 0.99 2.08 1.13 0.77 0.59 0.94
L1-RL 0.15 0.45 0.61 0.57 1.00 0.92 1.18
AL 1.39 0.88 2.27 1.19 0.70 0.64 0.90
L1-AL 0.34 0.60 0.94 0.60 0.99 0.81 1.16
QL 1.20 0.66 1.86 1.08 0.86 0.54 0.98
L1-QL 0.17 0.33 0.50 0.50 1.00 0.48 1.18
0.15
MCMEA 1.72 0.88 2.60 1.29 0.58 0.69 0.81
L1-MCMEA 0.30 0.51 0.81 0.61 0.99 0.85 1.15
RL 1.48 1.12 2.60 1.28 0.62 0.69 0.83
L1-RL 0.15 0.52 0.67 0.60 0.99 0.91 1.17
AL 1.71 0.99 2.69 1.31 0.56 0.71 0.80
L1-AL 0.39 0.76 1.15 0.67 0.97 0.83 1.15
QL 1.15 0.78 2.23 1.19 0.79 0.56 0.91
L1-QL 0.18 0.38 0.56 0.53 0.99 0.47 1.17
0.2
MCMEA 1.98 0.98 2.96 1.39 0.46 0.76 0.73
L1-MCMEA 0.36 0.67 1.03 0.67 0.98 0.83 1.14
RL 1.79 1.20 2.99 1.39 0.49 0.75 0.75
L1-RL 0.16 0.59 0.75 0.63 0.99 0.89 1.17
AL 1.95 1.10 3.06 1.40 0.44 0.77 0.73
L1-AL 0.50 1.00 1.50 0.75 0.96 0.81 1.13
QL 1.70 0.88 2.59 1.29 0.70 0.61 0.84
L1-QL 0.19 0.42 0.61 0.54 0.99 0.52 1.17
Note: In the presence of outliers, L1-MCMEA and L1-RL outperformed
their L2-based counterparts. The MSE and MAE decreased and sensitiv-
ity, specificity, and Q(η̂) increased with sample size.
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Table A.2: Simulation results of Setting 2.
ξo Sample Size Method Bias.sq Var MSE MAE Recall Specificity Q(η̂)
0.05
200
MCMEA 2.29 0.92 3.21 1.43 0.32 0.83 0.66
L1-MCMEA 1.32 1.34 2.65 1.20 0.72 0.62 0.92
RL 1.76 1.85 3.61 1.47 0.39 0.82 0.71
L1-RL 0.72 2.58 3.30 1.34 0.84 0.52 0.97
AL 2.28 1.49 3.77 1.52 0.26 0.88 0.64
L1-AL 1.31 2.77 4.08 1.40 0.60 0.67 0.86
QL 2.14 0.79 2.92 1.37 0.69 0.57 0.78
L1-QL 0.64 1.19 1.83 0.99 0.89 0.37 1.02
500
MCMEA 1.49 0.75 2.24 1.18 0.69 0.65 0.88
L1-MCMEA 0.50 0.65 1.14 0.74 0.97 0.71 1.11
RL 0.98 1.17 2.15 1.14 0.73 0.64 0.91
L1-RL 0.26 0.87 1.14 0.79 0.98 0.77 1.14
AL 1.48 0.97 2.44 1.23 0.63 0.70 1.10
L1-AL 0.53 1.04 0.82 0.82 0.96 0.67 0.91
QL 1.26 0.72 1.97 1.11 0.87 0.50 0.95
L1-QL 0.25 0.50 0.75 0.62 0.99 0.46 1.15
1000
MCMEA 0.92 0.59 1.51 0.95 0.90 0.50 1.04
L1-MCMEA 0.27 0.33 0.61 0.53 1.00 0.86 1.17
RL 0.55 0.79 1.34 0.88 0.94 0.49 1.07
L1-RL 0.15 0.41 0.55 0.55 1.00 0.91 1.18
AL 0.91 0.69 1.60 0.97 0.88 0.54 1.03
L1-AL 0.32 0.47 0.79 0.55 1.00 0.85 1.17
QL 0.76 0.54 1.30 0.88 0.96 0.46 1.07
L1-QL 0.17 0.31 0.48 0.48 1.00 0.43 1.18
0
200
MCMEA 1.22 0.73 1.95 1.04 0.84 0.61 1.00
L1-MCMEA 1.20 1.10 2.31 1.11 0.83 0.57 0.98
RL 0.45 0.96 1.41 0.85 0.98 0.62 1.10
L1-RL 0.73 2.23 2.96 1.26 0.88 0.53 1.01
AL 1.22 1.62 2.84 1.17 0.74 0.70 0.94
L1-AL 1.19 2.45 3.64 1.29 0.75 0.57 0.93
QL 1.34 0.33 1.67 1.01 0.93 0.70 1.03
L1-QL 0.56 1.03 1.59 0.93 0.92 0.34 1.05
500
MCMEA 0.57 0.26 0.83 0.65 1.00 0.51 1.15
L1-MCMEA 0.44 0.50 0.94 0.68 0.99 0.74 1.14
RL 0.26 0.25 0.51 0.48 1.00 0.62 1.18
L1-RL 0.28 0.76 1.04 0.74 0.99 0.81 1.14
AL 0.55 0.42 0.96 0.64 0.99 0.55 1.15
L1-AL 0.47 0.80 1.27 0.73 0.97 0.67 1.13
QL 0.48 0.29 0.76 0.55 1.00 0.31 1.14
L1-QL 0.24 0.45 0.69 0.59 0.99 0.42 1.16
1000
MCMEA 0.38 0.14 0.52 0.50 1.00 0.49 1.18
L1-MCMEA 0.27 0.27 0.54 0.52 1.00 0.88 1.18
RL 0.18 0.13 0.31 0.37 1.00 0.60 1.20
L1-RL 0.14 0.36 0.50 0.52 1.00 0.93 1.19
AL 0.35 0.19 0.54 0.47 1.00 0.53 1.18
L1-AL 0.28 0.37 0.64 0.52 1.00 0.86 1.18
QL 0.35 0.16 0.51 0.43 1.00 0.30 1.17
L1-QL 0.16 0.28 0.44 0.46 1.00 0.41 1.19
Note: In the presence of outliers, L1-MCMEA and L1-RL outperformed their L2-based
counterparts. The MSE and MAE decreased and sensitivity and specificity increased
with sample size.
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Table A.3: Simulation results of Setting 3.
ξo Dimension Method Bias.sq Var MSE MAE Recall Specificity Q(η̂)
0.05
10
MCMEA 0.92 0.59 1.51 0.95 0.90 0.50 1.04
L1-MCMEA 0.27 0.33 0.61 0.53 1.00 0.86 1.17
RL 0.55 0.79 1.34 0.88 0.94 0.49 1.07
L1-RL 0.15 0.41 0.55 0.55 1.00 0.91 1.18
AL 0.91 0.69 1.60 0.97 0.88 0.54 1.03
L1-AL 0.32 0.47 0.79 0.55 1.00 0.85 1.17
QL 0.76 0.54 1.30 0.88 0.96 0.46 1.07
L1-QL 0.17 0.31 0.48 0.48 1.00 0.43 1.18
30
MCMEA 1.06 0.61 1.67 1.05 0.87 0.73 1.01
L1-MCMEA 0.31 0.37 0.68 0.56 0.99 0.99 1.17
RL 0.62 0.89 1.51 0.98 0.85 0.75 0.99
L1-RL 0.18 0.42 0.60 0.59 1.00 0.98 1.18
AL 1.06 0.72 1.78 1.12 0.78 0.76 0.98
L1-AL 0.33 0.50 0.83 0.58 0.99 0.98 1.16
QL 0.87 0.61 1.48 0.96 0.87 0.72 1.00
L1-QL 0.25 0.33 0.58 0.50 0.99 0.99 1.17
50
MCMEA 1.14 0.63 1.77 1.12 0.80 0.82 1.01
L1-MCMEA 0.32 0.43 0.75 0.59 0.99 0.99 1.17
RL 0.69 0.92 1.61 1.05 0.79 0.81 0.98
L1-RL 0.21 0.44 0.65 0.61 0.99 0.98 1.18
AL 1.10 0.75 1.85 1.17 0.73 0.84 0.96
L1-AL 0.33 0.55 0.88 0.62 0.98 0.99 1.15
QL 0.96 0.62 1.58 1.04 0.83 0.75 0.98
L1-QL 0.29 0.34 0.63 0.52 0.98 0.99 1.17
0
10
MCMEA 0.34 0.08 0.42 0.48 1.00 0.49 1.18
L1-MCMEA 0.27 0.23 0.50 0.52 1.00 0.88 1.18
RL 0.18 0.24 0.42 0.47 1.00 0.60 1.20
L1-RL 0.14 0.32 0.46 0.50 1.00 0.93 1.19
AL 0.35 0.19 0.54 0.47 1.00 0.53 1.18
L1-AL 0.28 0.37 0.64 0.52 1.00 0.86 1.18
QL 0.35 0.16 0.41 0.43 1.00 0.30 1.17
L1-QL 0.16 0.28 0.44 0.46 1.00 0.41 1.19
30
MCMEA 0.35 0.12 0.47 0.51 1.00 0.54 1.18
L1-MCMEA 0.28 0.26 0.54 0.55 1.00 0.99 1.18
RL 0.20 0.26 0.46 0.50 1.00 0.60 1.19
L1-RL 0.19 0.32 0.51 0.53 1.00 0.98 1.19
AL 0.39 0.19 0.58 0.50 1.00 0.58 1.18
L1-AL 0.30 0.38 0.68 0.55 0.99 0.99 1.18
QL 0.30 0.15 0.45 0.46 0.99 0.97 1.13
L1-QL 0.16 0.32 0.48 0.49 0.99 0.99 1.19
50
MCMEA 0.37 0.15 0.52 0.54 1.00 0.60 1.17
L1-MCMEA 0.29 0.29 0.58 0.58 1.00 0.99 1.18
RL 0.21 0.27 0.48 0.53 1.00 0.61 1.17
L1-RL 0.21 0.35 0.56 0.56 1.00 0.99 1.19
AL 0.42 0.20 0.62 0.53 1.00 0.63 1.16
L1-AL 0.32 0.40 0.72 0.58 1.00 0.99 1.18
QL 0.32 0.17 0.49 0.49 1.00 0.97 1.09
L1-QL 0.20 0.32 0.52 0.52 0.98 1.00 1.18
Note: Effects of the covariate dimension. With the presence of outliers, the L1-based
methods outperformed the L2-based methods in MSE and MAE.
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A.5. Additional simulation settings and results
A.5.1. High-dimensional training sample with nonparametric independence
screening
We designed and conducted simulation on an additional parameter setting, to assess
the performance of the proposed methods in high-dimension situations. As described in
Section 2.3, we used NIS to screen the covariates in the first step.
We generated data as follows. the dimension of the covariates was indexed by p:
Xi ∼ Np(0,Σ), diag(Σ) = 1, Corr(Xij , Xik) = 0.5|j−k|, i = 1, ..., n,
Di|Xi ∼ Bernoulli(p(Xi)), Ti = 2Di − 1, logit(p(Xi)) = Xi1 −Xi2,
Yi = b0(Xi) +
Ti
2
τ0(Xi) + εi, εi ∼ (1− po)N(0, 1) + pologNormal(0, 4),
b0(Xi) = 0.5 + 4Xi1 +Xi2 − 3Xi3, τ0(Xi) = 2sin(2Xi1)−Xi2 + 3tanh(0.5Xi3),
where po is the proportion of outliers, n = 1000, po ∈ {0, 0.05}, and p ∈ {1000, 3000, 5000}
Figure A.1 shows that the NIS performed well in variable selection, especially when
there were outliers.
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Figure A.1: Influence of dimension.
Note: MSE and MAE tended to increase with dimension. But
when there were outliers, the L1-based methods (red line)
performed markedly better than the L2-based methods (black
line).
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Table A.4: Simulation results of Setting 4.
ξo Dimension Method Bias.sq Var MSE MAE Recall Specificity Q(η̂)
0.05
1000
MCMEA 0.65 0.78 1.43 0.89 0.91 1.00 1.07
L1-MCMEA 0.07 0.32 0.38 0.45 0.98 1.00 1.18
RL 0.61 0.88 1.50 0.91 0.89 1.00 1.06
L1-RL 0.06 0.40 0.46 0.50 0.98 1.00 1.18
AL 0.88 0.78 1.66 0.97 0.86 1.00 1.03
L1-AL 0.12 0.41 0.53 0.52 0.98 1.00 1.17
QL 0.78 0.71 1.50 0.91 0.94 1.00 1.07
L1-QL 0.09 0.32 0.40 0.46 0.98 1.00 1.18
3000
MCMEA 0.56 0.94 1.51 0.90 0.88 1.00 1.05
L1-MCMEA 0.07 0.41 0.48 0.49 0.95 1.00 1.17
RL 0.52 1.13 1.65 0.93 0.87 1.00 1.04
L1-RL 0.07 0.48 0.55 0.53 0.95 1.00 1.17
AL 0.77 1.01 1.78 0.98 0.84 1.00 1.02
L1-AL 0.15 0.51 0.66 0.56 0.95 1.00 1.16
QL 0.67 0.85 1.52 0.91 0.92 1.00 1.05
L1-QL 0.11 0.39 0.50 0.50 0.95 1.00 1.17
5000
MCMEA 0.72 0.96 1.68 0.95 0.86 1.00 1.04
L1-MCMEA 0.13 0.43 0.56 0.54 0.93 1.00 1.16
RL 0.67 1.10 1.77 0.97 0.85 1.00 1.04
L1-RL 0.12 0.52 0.64 0.57 0.93 1.00 1.16
AL 0.98 0.98 1.96 1.03 0.82 1.00 1.01
L1-AL 0.24 0.52 0.76 0.61 0.93 1.00 1.15
QL 0.86 0.84 1.70 0.96 0.91 1.00 1.05
L1-QL 0.17 0.42 0.58 0.53 0.93 1.00 1.16
0
1000
MCMEA 0.10 0.10 0.20 0.33 1.00 1.00 1.21
L1-MCMEA 0.06 0.22 0.28 0.41 1.00 1.00 1.20
RL 0.10 0.13 0.23 0.35 1.00 1.00 1.20
L1-RL 0.08 0.28 0.30 0.43 1.00 1.00 1.20
AL 0.17 0.12 0.29 0.37 1.00 1.00 1.19
L1-AL 0.11 0.21 0.32 0.39 1.00 1.00 1.19
QL 0.22 0.14 0.35 0.39 1.00 1.00 1.18
L1-QL 0.09 0.20 0.29 0.40 1.00 1.00 1.20
3000
MCMEA 0.12 0.10 0.23 0.35 1.00 1.00 1.21
L1-MCMEA 0.06 0.23 0.29 0.41 1.00 1.00 1.20
RL 0.11 0.13 0.24 0.36 1.00 1.00 1.20
L1-RL 0.06 0.28 0.33 0.45 1.00 1.00 1.20
AL 0.20 0.13 0.33 0.40 1.00 1.00 1.19
L1-AL 0.10 0.26 0.36 0.45 1.00 1.00 1.19
QL 0.22 0.15 0.38 0.41 1.00 1.00 1.18
L1-QL 0.08 0.23 0.31 0.41 1.00 1.00 1.20
5000
MCMEA 0.15 0.11 0.26 0.39 1.00 1.00 1.20
L1-MCMEA 0.11 0.24 0.35 0.28 1.00 1.00 1.20
RL 0.14 0.13 0.28 0.39 1.00 1.00 1.20
L1-RL 0.11 0.30 0.41 0.49 1.00 1.00 1.20
AL 0.25 0.13 0.38 0.43 1.00 1.00 1.19
L1-AL 0.18 0.28 0.46 0.51 1.00 1.00 1.19
QL 0.30 0.17 0.47 0.45 1.00 1.00 1.18
L1-QL 0.13 0.24 0.37 0.45 1.00 1.00 1.19
Note: In the presence of outliers, the L1-based methods performed markedly better
than the L2-based methods.
A.5.2. Effects of Smoothness Penalty
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Finally, we investigated the effects of an added smoothness penalty. We considered a
situation involving a univariate covariate x. We visualized the performance differences of
the L1 and L2 methods, with and without the smoothness penalty.
We generated the data as follows: Xi ∼ Unif(0, 1), τ(Xi) = 3sin(9(Xi − 0.5)), p(Xi) =
1/(1 + e−Xi), Yi = 1 +
Ti
2 τ0(Xi) + εi, εi ∼ 0.9N(0, 1) + 0.1logNormal(0, 4), the sample size
n = 1000, and the validation set with a size of 200. From Figures A.2 and A.3, it is clear
that the L1 methods outperform the L2 methods, and the L1 with smoothness penalty
greatly improved the performance of the estimation while reducing the variance. The 95%
Bootstrap C.I. coverage rate at selected point x ∈ {0.2, 0.5, 0.8} were listed in Table A.5.
The asymptotic variances of the L1-MCM-EA methods without penalty at selected point
x ∈ {0.2, 0.5, 0.8} are 0.130, 0.110, and 0.137, corresponding 95% asymptotic C.I. coverage
rates are 0.957, 0.973, and 0.959. The asymptotic variances of the L1-RL methods without
penalty at selected points are 0.129, 0.110, and 0.130, corresponding 95% asymptotic C.I.
coverage rates are 0.953, 0.969, and 0.957.
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Figure A.2: Effect of smoothness penalty.
Note: Panels on the left are L2-based methods with smooth-
ness penalty. Panels on the right are L1-based methods, also
with smoothness penalties. The black solid line is the estimate
from one replication, the black dashed lines represent quantile
95% bootstrap confidence interval from the same replication,
and the red solid line represents the true treatment effect func-
tion.
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Figure A.3: Effect of smoothness penalty.
Note: Panels on the left are L2 loss based methods without
smoothness penalties, panels on the right are L1- based meth-
ods without smoothness penalties. The black solid line is the
estimate from one replication, the black dashed lines represent
quantile 95% bootstrap C.I., the black dotted lines represent
the 95% asymptotic C.I. from the same replication, and the
red solid line represents the true treatment effect function.
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MCMEA 0.2 -1.28 0.773
0.5 0 0.955
0.8 1.28 0.791
L1-MCMEA 0.2 -1.28 0.954
0.5 0 0.956
0.8 1.28 0.945
RL 0.2 -1.28 0.784
0.5 0 0.962
0.8 1.28 0.798
L1-RL 0.2 -1.28 0.950
0.5 0 0.951
0.8 1.28 0.951
MCMEA w/o penalty 0.2 -1.28 0.927
0.5 0 0.928
0.8 1.28 0.931
L1-MCMEA w/o penalty 0.2 -1.28 0.955
0.5 0 0.968
0.8 1.28 0.963
RL w/o penalty 0.2 -1.28 0.929
0.5 0 0.926
0.8 1.28 0.931
L1-RL w/o penalty 0.2 -1.28 0.959
0.5 0 0.969
0.8 1.28 0.962
Note: The 95% asymptotic C.I. coverage rates of L1-
MCM-EA and L1-RL methods with penalty are close to
0.95, but that of L2-based methods could be far from
0.95.
A.5.3. Comparison of Q-learning and A-learning when model is miss-specified
We investigated the performance of Q-learning and proposed methods when model is
miss-specified. We summarize the MSE and MAE of the Q-learning and proposed methods
with combination of L1 and L2 loss when there is a small amount of outliers.
We generated the data as follows:
Xi ∼ Np(0,Σ), diag(Σ) = 1, Corr(Xij , Xik) = 0.5|j−k|, i = 1, ..., n,
Di|Xi ∼ Bernoulli(p(Xi)), Ti = 2Di − 1, logit(p(Xi)) = Xi1 −Xi2,
Yi = b0(Xi) +
Ti
2
τ0(Xi) + εi, εi ∼ (1− ξo)N(0, 1) + ξoLaplace(0, 10),
b0(Xi) = 0.5 +Xi1 +X
2
i2 − 6Xi3, τ0(Xi) = 2sin(2Xi1)−Xi2 + 3tanh(0.5Xi3),
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where n = 1000, q = 10, ξo = 0.1, and Q(η
















where we used L1 or L2 loss functions for ρ.
Table A.6: Simulation results of Setting 6
Method Bias.sq Var MSE MAE Recall Specificity Q(η̂)
MCMEA 1.50 0.82 2.32 1.21 0.68 0.63 1.85
L1-MCMEA 0.18 0.64 0.82 0.62 0.99 0.74 2.14
RL 1.57 0.73 2.30 1.21 0.68 0.65 1.86
L1-RL 0.19 0.63 0.83 0.61 0.99 0.73 2.15
AL 1.43 0.89 2.32 1.20 0.69 0.65 1.87
L1-AL 0.35 2.25 2.61 0.84 0.94 0.75 2.12
QL 1.66 1.11 2.76 1.31 0.74 0.63 1.81
L1-QL 3.57 1.01 4.58 1.15 1.00 0.52 2.08
Note: When model is mis-specified, L1-QL and L2-QL have the
largest MSE compared with other methods.
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A.6. Existence of outliers
The following figure shows that the outcome observations in both treatment groups are
beyond normally distributed.
Figure A.4: Heavy-tailed Systolic Blood Pressure Distribution
A.7: Nuisance parameter estimation
The GBM is used to estimate mean outcome and propensity score. The estimation of two
groups are as following figure.
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Figure A.5: Histograms of the mean outcomes and the estimated propensity score in the
two treatment groups. The mean functions had similar shapes whereas the propensity
distributions were clearly different.
In the application of proposed method, the importance levels from GBM are consistent
with the result from regression. The importance levels from GBM and the linear and logistic
regression results are summarized in the following two tables.
Table A.7: Importance levels from the GBM analysis vs coefficients and p-values from
regression analysis.
Variable Importance (scaled) Linear regression coefficient Linear regression p-value
Average PDC 100.0000 -8.3352 <0.001*
BMI 71.4317 0.1217 0.022*
Pulse 57.9355 0.0829 0.052
Male 51.0437 5.3345 <0.001*
Age 40.9329 0.1421 <0.001*
Depression 21.7349 -2.7787 0.007*
CAD 9.6647 3.9908 0.181
Diabetes 8.3385 -1.4464 <0.001*
Stroke 5.7007 3.9820 0.242
Hyperlipidemia 3.3518 -0.6630 0.581
Black 2.9593 0.8341 0.351
CKD 1.6875 -4.6852 0.101
COPD 0.7970 -1.6243 0.272
CHF 0.3214 1.4062 0.668
Atrial fibrillation 0 0.2215 0.968
MI 0 -5.3773 0.405
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Table A.8: Propensity models based on GBM and logistic regression
Variable Importance (scaled) Logistic regression coefficient Logistic regression p-value
BMI 100.0000 0.0342 <0.001*
Pulse 75.3721 -0.0162 0.028*
Age 65.0922 0.0205 0.002*
Diabetes 61.9452 -1.2126 <0.001*
Black 27.7566 0.7032 <0.001*
Male 8.5503 -0.2410 0.123
Hyperlipidemia 5.2229 0.3572 0.091
Depression 3.3688 0.2294 0.200
COPD 2.6379 -0.2325 0.353
CAD 2.0312 0.2867 0.577
Stroke 1.9077 -0.9878 0.086
CKD 1.1372 0.1413 0.772
CHF 0.5027 0.1182 0.834
MI 0 0.4516 0.678





R-package for robust estimation of CATE: R package RCATE contains code of 9
robust estimation algorithms of CATE described in the Chapter 3 and also the meth-
ods based on additive B-spline LAD regression in Chapter 2. The package also contains
the dataset used as example in this dissertation.
Hypertension dataset: Data set used in the illustration of robust estimation of CATE
algorithms in Section 3.2.
Example of usage: A simple simulated example.
## I n s t a l l package
require ( dev too l s )
dev too l s : : in s ta l l github ( ” r h l i −Hannah/RCATE” )
l ibrary (RCATE)
## Data g e n e r a t i o n
n <− 1000 ; p <− 3 ; set . seed (2223)
X <− as . data . frame (matrix ( runif (n∗p , −3 ,3) ,nrow=n , ncol=p ) )
tau = 6∗sin (2∗X[ ,1 ] )+3∗ (X[ , 2 ]+3)∗X[ , 3 ]
p = 1/(1+exp(−X[ ,1 ]+X[ , 2 ] ) )
d = rbinom(n , 1 , p )
t = 2∗d−1
y = 100+4∗X[ ,1 ]+X[ ,2 ] −3∗X[ ,3 ]+ tau∗t/2 + rnorm(n , 0 , 1 )
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set . seed (2223)
x va l = as . data . frame (matrix (rnorm(200∗3 , 0 , 1 ) ,
nrow=200 ,ncol=3))
tau va l = 6∗sin (2∗x va l [ , 1 ] )+3∗ ( x va l [ , 2 ]+3)∗x va l [ , 3 ]
## Use r o b u s t GBM + R−l e a r n i n g to e s t i m a t e CATE
f i t <− r c a t e . ml (X, y , d , method=’RL ’ , a lgor i thm=’GBM’ )
y pred <− predict ( f i t , x va l )$predict
plot ( tau val , y pred ) ; abline ( 0 , 1 )
Figure B.1: Comparison of τ0 and τ̂ from the example of the RCATE package
## Variab l e importance l e v e l
importance <− importance . r c a t e ( f i t )
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Figure B.2: Variable importance from the example of the RCATE package
## Marginal t reatment e f f e c t p l o t
marginal . r c a t e ( f i t , ’V1 ’ )
marginal . r c a t e ( f i t , ’V3 ’ )
(a) Marginal effect of V 1 (b) Marginal effect of V 2
Figure B.3: Marginal treatment effects of selected variables from the example of the
RCATE package
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Appendix B.2: Simulation Results





po 0.00 0.05 0.10 0.15 0.20 0.30 0.50 0.00 0.05 0.10 0.15 0.20 0.30 0.50
robust GBM 95 94 91 93 93 95 97 95 94 95 94 94 98 97
GBM 95 93 96 96 94 97 96 95 96 97 99 99 91 95
robust NN 95 94 96 92 94 99 98 95 92 98 92 95 98 93
NN 96 76 87 47 83 79 89 96 39 43 27 32 35 29
robust RF 94 96 97 94 92 93 98 94 95 94 93 92 96 98
RF 96 96 98 97 97 89 96 96 90 92 92 93 89 87
robust GAM 23 38 49 54 57 66 74 23 39 48 54 59 66 76





po 0.00 0.05 0.10 0.15 0.20 0.30 0.50 0.00 0.05 0.10 0.15 0.20 0.30 0.50
robust GBM 95 94 95 96 95 97 97 95 95 96 94 96 91 98
GBM 93 97 98 98 97 96 95 93 99 98 99 100 100 99
robust NN 94 95 93 96 92 93 96 94 95 96 93 97 91 98
NN 96 82 94 95 88 85 91 96 94 93 94 85 82 36
robust RF 95 96 97 94 98 95 94 95 92 91 90 87 82 72
RF 94 89 98 97 87 93 94 94 82 93 89 95 89 86
robust GAM 27 48 57 61 65 71 80 27 49 58 64 65 72 81





po 0.00 0.05 0.10 0.15 0.20 0.30 0.50 0.00 0.05 0.10 0.15 0.20 0.30 0.50
robust GBM 96 93 92 91 90 89 90 96 94 93 92 90 98 93
GBM 96 92 98 97 95 95 98 96 97 96 99 97 90 91
robust NN 94 92 95 93 92 96 98 94 98 96 93 95 93 98
NN 95 74 89 96 80 73 88 95 44 88 84 87 83 78
robust RF 93 94 98 91 97 96 98 93 96 97 94 95 96 95
RF 94 98 97 93 93 82 96 94 94 91 87 95 86 82
robust GAM 54 57 59 61 62 64 70 54 58 59 61 64 66 73
robust QL 47 49 49 52 53 53 0 47 49 50 51 53 33 0
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n 200 400 600 800 1000 200 400 600 800 1000
MSE
robust GBM 3.43 2.28 1.66 1.39 1.14 4.08 2.43 1.80 1.55 1.37
GBM 19.96 13.87 10.95 8.99 7.69 21.64 14.18 11.33 9.36 7.33
robust NN 5.70 2.25 1.54 1.12 1.00 5.84 2.45 1.74 1.21 1.14
NN 6.50 3.95 3.01 2.60 2.17 6.79 4.09 3.01 2.69 2.23
robust RF 2.96 2.10 1.53 1.37 1.24 3.21 2.05 1.55 1.54 1.25
RF 11.12 9.94 8.77 7.94 7.75 10.05 9.37 8.33 8.38 7.23
robust GAM 1.54 2.54
n 200 400 600 800 1000 200 400 600 800 1000
MAE
robust GBM 1.44 1.32 0.99 0.90 0.80 1.57 1.21 1.03 0.94 0.87
GBM 3.40 3.56 2.49 2.23 2.05 3.62 2.91 2.58 2.34 2.06
robust NN 1.86 1.14 0.93 0.80 0.75 1.89 1.19 0.98 0.83 0.79
NN 1.99 1.53 1.33 1.23 1.14 2.04 1.57 1.34 1.26 1.14
robust RF 1.27 0.99 0.90 0.84 0.79 1.32 1.03 0.89 0.89 0.80
RF 2.02 3.56 1.80 1.73 1.70 2.08 4.08 1.89 1.83 1.75





n 200 400 600 800 1000 200 400 600 800 1000
MSE
robust GBM 4.87 2.88 2.19 1.77 1.52 6.46 3.19 2.36 2.05 1.77
GBM 36.93 22.98 17.28 14.28 11.88 38.67 24.42 17.34 16.77 11.55
robust NN 6.19 2.48 1.48 1.23 1.04 6.28 2.67 1.44 1.33 1.07
NN 6.78 4.28 3.45 2.87 2.60 7.30 4.39 3.51 3.10 2.62
robust RF 3.32 2.24 1.76 1.59 1.39 4.14 2.92 2.20 1.92 1.34
RF 49.57 49.48 9.36 43.16 47.60 133.48 92.12 40.54 68.37 50.74
robust GAM 1.87 3.03
n 200 400 600 800 1000 200 400 600 800 1000
MAE
robust GBM 1.71 1.32 1.07 1.01 0.93 1.95 1.38 1.18 1.08 1.00
GBM 4.56 3.56 2.50 2.73 2.48 4.78 3.71 3.16 2.97 2.53
robust NN 1.94 1.19 0.91 0.83 0.77 1.96 1.23 0.92 0.87 0.78
NN 2.03 1.60 1.43 1.31 1.24 2.12 1.63 1.44 1.36 1.26
robust RF 1.27 0.99 0.86 0.81 0.72 1.36 1.03 0.87 0.85 0.77
RF 3.61 3.56 1.81 3.57 3.67 4.61 4.08 3.64 4.35 3.89





n 200 400 600 800 1000 200 400 600 800 1000
MSE
robust GBM 4.55 3.13 2.09 1.70 1.41 5.23 3.15 2.36 1.87 1.73
GBM 19.10 14.01 11.75 8.61 7.32 20.36 13.40 12.07 9.90 7.52
robust NN 5.12 2.17 1.57 1.18 0.94 5.88 2.48 1.58 1.24 0.99
NN 1.97 3.77 2.91 2.46 2.23 6.86 4.24 3.14 2.57 2.34
robust RF 2.80 1.98 1.36 1.29 1.18 3.25 1.98 1.56 1.37 1.18
RF 10.57 9.66 9.36 8.58 8.33 9.98 8.81 9.21 9.86 8.66
robust GAM 2.52 3.04
n 200 400 600 800 1000 200 400 600 800 1000
MAE
robust GBM 1.65 1.33 1.07 0.94 0.84 1.77 1.33 1.13 0.99 0.92
GBM 3.35 2.78 2.50 2.13 1.98 3.50 2.81 2.59 2.31 2.05
robust NN 1.76 1.11 0.93 0.81 0.73 1.89 1.19 0.96 0.84 0.76
NN 1.97 1.50 1.31 1.20 1.15 2.05 1.59 1.37 1.23 1.17
robust RF 1.21 0.99 0.86 0.82 0.78 1.32 1.01 0.89 0.84 0.77
RF 1.98 1.89 1.81 1.73 1.68 2.09 1.94 1.92 1.87 1.76
robust GAM 0.99 1.11
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n 1000 3000 5000 7000 1000 3000 5000 7000
MSE
robust GBM 1.85 1.01 0.80 0.80 1.83 0.97 0.83 0.77
GBM 11.22 2.71 1.99 1.55 11.10 2.83 2.03 1.59
robust NN 1.48 1.04 0.84 0.78 1.46 1.03 0.86 0.84
NN 2.76 2.61 2.18 1.88 2.74 2.76 2.20 1.95
robust RF 1.63 1.31 1.01 0.84 1.62 1.17 0.96 0.88
RF 5.12 5.00 4.28 4.13 5.26 4.85 4.11 3.81
robust GAM 0.87 0.88
n 1000 3000 5000 7000 1000 3000 5000 7000
MAE
robust GBM 1.06 0.75 0.67 0.61 1.06 0.74 0.68 0.68
GBM 2.56 1.23 1.05 0.93 2.58 1.28 1.07 0.94
robust NN 0.94 0.77 0.69 0.62 0.93 0.77 0.70 0.72
NN 1.28 1.23 1.13 1.04 1.28 1.27 1.13 1.07
robust RF 0.94 0.84 0.72 0.67 0.92 0.79 0.71 0.68
RF 1.51 1.48 1.40 1.36 1.58 1.53 1.44 1.37





n 1000 3000 5000 7000 1000 3000 5000 7000
MSE
robust GBM 2.21 0.72 0.45 0.30 2.27 0.72 0.45 0.30
GBM 29.31 4.55 3.01 2.14 27.49 5.02 3.04 1.80
robust NN 1.29 0.77 0.53 0.36 1.36 0.80 0.55 0.37
NN 3.58 3.26 2.58 1.90 3.66 3.51 2.55 1.93
robust RF 0.98 0.73 0.60 0.50 1.09 0.85 0.70 0.62
RF 107.18 91.18 91.12 72.19 127.63 91.68 81.65 70.37
robust GAM 0.64 0.61
n 1000 3000 5000 7000 1000 3000 5000 7000
MAE
robust GBM 1.14 0.64 0.50 0.40 1.15 0.63 0.49 0.40
GBM 3.80 1.51 1.20 0.97 3.75 1.59 1.25 0.96
robust NN 0.88 0.67 0.55 0.46 0.90 0.68 0.56 0.46
NN 1.45 1.37 1.22 1.04 1.47 1.42 1.22 1.06
robust RF 0.71 0.62 0.54 0.46 0.70 0.60 0.51 0.47
RF 5.44 4.89 4.61 4.04 5.73 4.96 4.65 4.19





n 1000 3000 5000 7000 1000 3000 5000 7000
MSE
robust GBM 2.46 1.55 0.82 0.60 2.99 1.29 1.07 0.98
GBM 14.43 3.98 2.47 1.54 15.25 3.51 4.17 1.88
robust NN 1.43 0.94 0.66 0.43 1.46 0.89 0.63 0.43
NN 3.83 3.27 2.54 2.04 3.61 3.15 2.67 2.06
robust RF 1.28 1.00 0.73 0.57 1.35 0.93 0.75 0.63
RF 7.80 7.76 7.51 6.20 7.97 7.39 7.09 6.72
robust GAM 0.63 0.75
n 1000 3000 5000 7000 1000 3000 5000 7000
MAE
robust GBM 1.48 0.77 0.59 0.48 1.15 0.76 0.61 0.48
GBM 2.82 1.37 1.10 0.85 2.87 1.37 1.11 0.85
robust NN 0.92 0.73 0.61 0.49 0.93 0.72 0.60 0.49
NN 1.46 1.35 1.20 1.07 1.46 1.34 1.23 1.07
robust RF 0.81 0.71 0.59 0.47 0.83 0.69 0.60 0.53
RF 1.65 1.64 1.56 1.45 1.69 1.69 1.59 1.55
robust GAM 0.52 0.53
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Table B.4: Tuning parameters of considered methods in experiments
Method Parameter Value
RF-based algorithms
Number of trees 50
Fraction of feathers used in splitting 0.8
Minimum node size 3
Boosting-based algorithms
Number of trees 1000
Depth of trees 2
Learning rate 0.1
Robust ANN
Number of hidden layers 2
Number of neurons in hidden layers p and p/2
Adam optimization α = 0.001, β1 = 0.9, β2 = 0.999
L1 regularization
(p = 100, 2000)
0.1, if p = 100; 0.02, if p = 2000.
Number of neurons in hidden layers
(p = 2000)
p/10 and p/40




Number of degree 3
γ in SCAD 3.7
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